

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## A pilot test for the reopening of nightclubs and other late-night venues during the COVID-19 pandemic: 'Reobrim Sitges'

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058595
Article Type:	Original research
Date Submitted by the Author:	27-Oct-2021
Complete List of Authors:	Cunillera Puértolas, Oriol; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona Contreras-Martos, Sara; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona Marzo-Castillejo, Mercè; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona López Gallegos, Darío; Institut Català de La Salut, Servei d'Atenció Primària Alt Penedès-Garraf-Baix Llobregat Nord, Direcció d'Atenció Primària Costa de Ponent Acedo Anta, Mateo; Institut Català de la Salut, Secretaria Tècnica, Direcció d'Atenció Primària Costa de Ponent; Universitat de Barcelona Facultat de Medicina i Ciències de la Salut, Escola d'Infermeria Almeda Ortega, Jesús; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona Colom, Joan; Agència de Salut Pública de Catalunya, Sub-direcció General de Drogodependències Basora, Josep; IDIAP Jordi Gol, Institut Universitari d'Investigació en Atenció Primària Salvador-Gonzalez, Betlem; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona
Keywords:	COVID-19, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Public health < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

A pilot test for the **reopening of nightclubs** and other late-night venues during the **COVID-19 pandemic: 'Reobrim Sitges'**

Oriol Cunillera Puértolas<sup>1,2</sup>

Sara Contreras-Martos<sup>1,2,3</sup>

Mercè Marzo- Castillejo<sup>1,2,3</sup>

Darío López Gallegos<sup>4</sup>

Mateo Acedo Anta<sup>5,6</sup>

Jesús Almeda Ortega<sup>1,2,3</sup>

Joan Colom Farran<sup>7</sup>

Josep Basora i Gallisà<sup>8</sup>

Betlem Salvador González<sup>1,3</sup>

1-Unitat de Suport a la Recerca Costa de Ponent, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Cornellà de Llobregat, Spain

2-Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain.

3-Unitat de Suport a la Recerca, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la Salut, L'Hospitalet de Llobregat, Spain

4-Servei d'Atenció Primària Alt Penedès-Garraf-Baix Llobregat Nord, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la Salut, L'Hospitalet de Llobregat, Spain.

5-Secretaria Tècnica, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la Salut, Cornellà de Llobregat, Spain.

6-Escola d'Infermeria, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

7-Subdirecció General de Drogodependències. ASPCAT. Departament de Salut, Generalitat de Catalunya, Barcelona, Spain.

8-Institut Universitari d'Investigació en Atenció Primària (IDIAP Jordi Gol), Barcelona, Spain.

\* *Corresponding author:* Betlem Salvador-González

C/ Bellaterra, 41, 1er pis 08940 Cornellà de Llobregat, Barcelona. [bsalvador@ambitcp.catsalut.net](mailto:bsalvador@ambitcp.catsalut.net)

Word count: 3086 words

## ABSTRACT

Background: The economic impact of governmental legal restrictions during COVID-19 pandemic requires evaluation of the balance between health and economy. This study aims to assess the health impact of reopening the local nightlife under controlled conditions.

Methods: Observational study with a paired control group (1:5 ratio), performed in a nightlife restricted area in Sitges on May 2021. Volunteers were selected through a convenience sampling. Participants, aged over 17, presented negative Ag-RDT test on the same afternoon, and not having a positive RT-PCR or Ag-RDT test and/or symptoms associated with COVID-19 in the last 7 days, not being close contact with someone infected in the last 10 days, or having had close contact with someone with a suspicion of COVID-19 in the last 48 hours was required to access the event. Mask was mandatory, drinking was allowed and no social distance was required. The main outcome was evidence of infection by SARS-CoV-2 at 14 days follow-up.

Results: Of the 391 participants no positive SARS-CoV-2 cases were detected at 14 days, resulting in an estimation of a cumulative incidence (95% confidence interval) of 0 (0, 943.45) /100,000 inhabitants. In the control group, 2 cases with RT-PCR test were identified, a cumulative incidence of 102.30 (12.39, 369.55) /100,000 inhabitants.

Conclusions: Attendance to night-clubs under controlled conditions and previous negative Ag-RDT did not show an increased transmissibility of SARS-CoV-2. Secure aperture of nightlife sector is possible under reduced capacity limits, controlled access by Ag-RDT, and environments where compliance of sanitary measures conditions are maintainable.

### Strengths and limitations of this study

- No studies have focused on the reopening of the more common sources on nightlife under the COVID-19 pandemic: small clubs.
- This is an observational study with a convenience sampling, with a paired control group.
- Participants performed Ag-RDT tests the afternoon of the event's day. Ag-RDT follow-up tests 6 days after the intervention minimized unregistered infections in the exposed group
- Setting: 5 nightclubs with interior areas and exterior terraces, wearing masks was mandatory, drinking was allowed, and social distance was not required.

## INTRODUCTION

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic had infected 186 million people and caused over 4 million deaths worldwide by July 12<sup>th</sup> 2021, with wide variability between countries and regions [1]. The SARS-CoV-2 transmission mostly occurs by direct contact or through droplets and aerosols from an infected person located within 2 meters range and exposition times over 15 minutes [2,3]. Indoor, poorly ventilated, crowded spaces [4] where people gather are hotspots for the transmission of virus [5].

The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, has an incubation period that varies from 2 to 14 days. Among the symptomatic people, 50% develop symptoms within 5.1 days and 75% within 11.5 days [6].

The gold standard diagnostic test for SARS-Cov-2 is the real-time reverse-transcription polymerase chain reaction (RT-PCR), which detects viral RNA, presenting good results in terms of reliability, sensibility and specificity [7]. Although RT-PCR can detect positive cases from the beginning of the infection in symptomatic and asymptomatic people, the need for well-equipped labs with specialized professionals increases the total delivery times and costs [8]. In contrast, the lateral flow immunochromatographic rapid antigen diagnostic tests (Ag-RDT) for SARS-CoV-2 can detect viral proteins and provide results *in situ* within less than 30 minutes; despite its sensitivity is below WHO's recommendations, Ag-RDTs still offer the possibility of rapid, easy and inexpensive detection of SARS-CoV-2 in individuals who have high viral loads and hence are at high risk of transmitting the infection to others [9], which is the relevant issue for most public health measures [10].

The sanitary and social crisis subsequent to the COVID-19 pandemic have forced many governments to deploy new social policies and legal restrictions, mostly focused on reducing the spreading of COVID-19. In Spain, restrictions to mobility and economic activity -with temporal closure of restaurants, hotels and nightlife activities - began with the first alarm state on March 2020 [11]. Currently, some restrictions on capacity limitations and opening hours still prevail. The balance between health and economy is still on study in the more flexible stage we are in: bars, restaurants, pubs, discotheques, and concert venues were still on the tightrope, claiming for secure measures allowing them to flounder.

The herd-immunity, mainly through massive vaccination, is the key goal to restore social and economic activities in this sector. In Catalunya, on May 5th 2021, a 30.5% of the population had received at least one dose, and a 13.6% had completed vaccination [12]. Due to age prioritisation, only 6.9% of 18-24 years old Catalans and 11% of aged 25-49 had some vaccination, thus constituting age ranges where legal measures were still prominent on controlling virus transmission.

Some studies have been carried out in Catalunya to assess the impact of losing legal restrictions on various types of social activities, including indoor gigs and dining passes in restaurants; although just two articles have been published up to date [13,14], press conferences have spread some results on three initiatives [15]. None of these studies detected any increased risk associated with the expositions.

The present study is another step in generating evidence on the safety reopening of social activities in Catalonia. We aimed to assess the impact of loosening alarm state restrictions in small clubs nightlife on SARS-CoV-2 infections at 14 days.

## METHODS

This is an observational study with a paired control group, performed in a nightlife restricted area in Sitges (Barcelona, Spain) on May 20th 2021.

The volunteer attending the event were recruited by convenience sampling promoted -mainly through social networks- by participant entities (council, guild, locals) and registered through the official city council web. Inclusion and exclusion criteria for all exposition groups (formed by study volunteers and staff groups) are defined in table 1. Participants performed their Ag-RDT tests in scheduled intervals the afternoon of the event's day in Sitges. The Ag-RDT test was performed by trained health professionals following manufacture's instructions (AllTest, Ref. ICOV-502, Japan). Manufacturers' reported sensitivity and especificity were 96.4% and 99.9%, respectively.

**Table 1.** Inclusion and exclusion criteria for study participants (volunteers and staff groups) attending the nightlif mass-gathering event

Inclusion criteria	Exclusion criteria
1. Aged over 17	1. Declaring to have a positive RT-PCR or Ag-RDT test in the last 7 days
2. Living in Sitges area and Barcelona	2. Presenting symptoms associated with COVID-19 in the last 7 days (according to Catalan Health Department protocols [16,17]):
3. Having an individual health card of the Catalan public healthcare system	a) <i>at least one of these: fever, persistent cough, shortness of breath, anosmia, ageusia</i>
4. A negative Ag-RDT test the same afternoon (provided by the organization)	b) <i>at least two of the following: sore throat, a cold, fatigue, myalgia, headache, vomiting or diarrhea stomach ache</i>
	3. Having had close contact with someone infected in the last 10 days
	4. Having had close contact with someone with a suspicion of COVID-19 in the last 48 hours

The nightlife event was developed from 23:00 p.m. of May 20th to 3:00 a.m of May 21st, in a restricted street section, including 5 nightclubs with interior areas (capacity 42-98 people) and exterior terraces (capacity 15-35 people), with controlled registered access exclusively for participants. Mask was mandatory (quirurgical or FFP2). Drinking was allowed indoors and

1  
2  
3 outdoors. Social distance was not required. Hydroalcoholic gel and panels reminding COVID-  
4 19 safety standards and their participation in the study were distributed throughout all the area.  
5 A follow-up Ag-RDT test on day 6 after the event was performed on participants.  
6

7  
8 The control group was obtained through secondary data from the primary care electronic  
9 health records (PC-EHR), by a pseudonymized paired extraction of individuals not attending  
10 the social event. Pairing was executed by exact age, sex, residence municipality,  
11 socioeconomic index, previous SARS-CoV-2 confirmed infection, and vaccination status (at  
12 least one dose administered), by a 1:5 ratio.  
13

14  
15 Sample size was conditioned on capacity limitations fixed on 75% of the locals' usual limits,  
16 resulting in 400 volunteers. Considering the 14 days cumulative incidence of COVID-19  
17 occurring in the health district (Gerència Territorial Metropolitana Sud) on April 29th 2021  
18 (210.46/100,000 inhabitants [<https://dadescovid.cat/>]), significant differences would be found  
19 observing a 14 days incidence in the intervention group of 1.38% (6 positive cases), with a  
20 level of significance of 0.05 and power of 0.8.  
21

## 22 23 **Variables**

24  
25 The main outcome was confirmed case (PCR, Ag-RDT and serology) of SARS-CoV-2  
26 infection at 14 days follow-up. As a secondary outcome, the number of positive Ag-RDTs  
27 performed presencially at 6 days in the exposition group was considered. The main outcome  
28 was gathered from both the 6 days follow-up Ag-RDT and any registry in the PC-EHR at 14  
29 days follow-up for the exposition group, an only from PC-EHR for the control group.  
30

31  
32 All other variables were obtained from PC-EHR: age, sex, MEDEA socioeconomic deprivation  
33 index [18] (classifying individuals into septiles), previous SARS-CoV-2 confirmed infection  
34 and previous vaccination: first and second intake, date, and vaccine commercial brand  
35 (BioNTech - Pfizer / Moderna / Oxford AstraZenecae/Janssen-Johnson&Johnson).  
36

37  
38 This information was collected for all participants, which were categorized according to their  
39 role as Organizers, Security personnel, Club workers, or Volunteers.  
40

## 41 42 **Statistical analysis**

43  
44 All variables were described and compared by participant role groups. Median, interquartile  
45 range, mean and standard deviation were calculated for continuous variables, and absolute  
46 and relative frequencies were described for categorical variables. Homogeneity in distribution  
47 across roles was tested using Kruskal-Wallis or Chi-square tests and complete case analysis.  
48 As pairing was performed by the exact characteristics, no description will be provided for the  
49 controls (presenting the same values as study participants).  
50

51  
52 Cumulative incidence was calculated for study participants as the number of positive cases at  
53 14 days divided by the total of individuals exposed, transformed into cases per 100,000  
54 inhabitants, and with confidence intervals estimated by the exact method.  
55

## 56 57 **Patient and Public Involvement**



1  
2  
3  
4  
5 The Associació d'Establiments d'Oci Nocturn de Sitges (Association of Nightlife Premises of  
6 Sitges) and the Federació Catalana de Locals d'Oci Nocturn (Catalan Federation of  
7 Nightclubs) proposed and promoted the initiative and developed with The Sitges Council the  
8 initial proposal. The Catalan Public Health Agency was contacted to adapt it to a formal study  
9 design and develop it, with the aforementioned entities participating in the conception and  
10 dissemination. There was an immediate return of results to the entities to allow their  
11 dissemination  
12  
13

### 14 **Ethical considerations**

15 This study was approved by the Research Ethics Committee of the Institute for Primary Health  
16 Care Research Jordi Gol i Gurina (IDIAPJGol) and the Technical Committee of the Civil  
17 Protection Plan of Catalonia (PROCICAT). The study guarantees compliance with the new  
18 General Data Protection Regulation (GDPR) EU 2016/679, the guidelines of the Principles of  
19 the Declaration of Hèlsinki and the Belmont Report.  
20  
21

22 Participants were informed about the project and signed a responsible statement and informed  
23 consent to participate and allowed the use of their pseudonymized data exclusively for this  
24 project. Informed consent was not required for participants in the control group as the  
25 information was pseudonymized.  
26  
27

28 The external entity 'Curasana' ([www.curasana.org](http://www.curasana.org)) was responsible for the logistic and  
29 performance of Ag-RDT tests. Results were sent to the Catalan Institute of Health (ICS);  
30 positive results were communicated and introduced to EHR for assistance purposes. The ICS  
31 and the IDIAPJGol were independently responsible for the data processing within the  
32 framework of this study.  
33  
34  
35  
36  
37  
38  
39

### 40 **RESULTS**

41 No positive Ag-RDTs tests were detected at baseline. The final exposition group was  
42 composed of 391 participants (332 volunteers, 9 security staff, 32 bartenders/DJs, 18  
43 organizers) that accessed the nightlife restricted area. Participants had a median/mean age  
44 of 37/37.5 years, 50% were between 23 and 50 years (Table 2). 55.7% were male, and there  
45 was an underrepresentation of extreme catalan socioeconomic ranges (specially the least  
46 deprived, with a 4.1% in front of the 28.6% in general population). About 9.0% had been  
47 previously infected by SARS-CoV-2, 10.7% had at least one vaccination dose, and 1.0% had  
48 been both vaccinated and infected.  
49  
50  
51

52 Staff groups were significantly different than volunteers in terms of age (organizers were  
53 significantly older), sex (due to a 100% male security personnel) and socioeconomic status  
54 (55.5% of security personnel came from most deprived areas). Although not significant,  
55 security personnel and bartenders/DJs had lower percentages of vaccination and previous  
56 infection. As control group was matched by exact characteristics, it presented the exact same  
57 distribution for all variables except for the outcomes.  
58  
59  
60

1  
2  
3 Volunteers stayed in the local nightlife delimited area for a mean of 177 minutes (minimum-  
4 maximum: 59-210 minutes). 88% of participants attended the 6 days Ag-RDT, all of them with  
5 negative results.  
6

7  
8 No positive SARS-CoV-2 cases were detected at 14 days in the exposition group, (estimated  
9 cumulative incidence (95% confidence interval): 0 (0, 943.45) / 100,000 inhabitants) and 2  
10 positive RT-PCR cases in the control group (cumulative incidence of 102.30 (12.39, 369.55) /  
11 100,000 inhabitants).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 2. Sample characteristics and outcomes in the sample of participants in the ‘Reobrim Sitges’ study, Overall and by role groups.

	n	Missings	Global	Organizers (n=18)	Security personnel (n=9)	Club workers (n=32)	Study Participants (n=332)	p-value
Age : Median [IQR]	391	0	37.00 [23.00, 50.00]	54.00 [48.25, 57.00]	41.00 [38.00, 46.00]	29.00 [25.00, 40.25]	35.50 [23.00, 50.00]	<0.001
Age : Mean (SD)			37.54 (15.53)	51.67 (8.60)	41.44 (6.95)	33.06 (10.53)	37.10 (15.99)	<0.001
Sex : n (%)	391	0						0.017
<i>Women</i>			173 (44.25%)	8 (44.44%)	0 (0.00%)	10 (31.25%)	155 (46.69%)	
<i>Men</i>			218 (55.75%)	10 (55.56%)	9 (100.00%)	22 (68.75%)	177 (53.31%)	
MEDEA Deprivation Index : Median [IQR]	374	17	-0.32 [-0.32, 0.48]	-0.32 [-0.32, -0.14]	0.64 [0.48, 1.07]	-0.32 [-0.32, 0.64]	-0.32 [-0.32, 0.48]	0.022
MEDEA Deprivation Index : Mean (SD)			0.04 (0.59)	-0.03 (0.64)	0.79 (0.49)	0.09 (0.67)	0.02 (0.58)	0.015
MEDEA Deprivation Index Categories: n (%)	391	0						<0.001
<i>Least deprived Septiles (28.6%)</i>			16 (4.09%)	0 (0.00%)	0 (0.00%)	1 (3.12%)	15 (4.52%)	
<i>Most deprived Septiles (28.6%)</i>			98 (25.06%)	3 (16.67%)	5 (55.56%)	9 (28.12%)	81 (24.40%)	
<i>3 Central Septiles (42.8%)</i>			260 (66.50%)	13 (72.22%)	1 (11.11%)	21 (65.62%)	225 (67.77%)	
<i>No Medea</i>			17 (4.35%)	2 (11.11%)	3 (33.33%)	1 (3.12%)	11 (3.31%)	
Previous infection : n (%)	391	0	35 (8.95%)	3 (16.67%)	0 (0.00%)	2 (6.25%)	30 (9.04%)	0.477
Previous infection date : Median (IQR)	35	356	2020-11-02 [2020-08-17, 2021-01-08]	2021-01-13 [2020-11-04, 2021-01-17]	-	2021-01-19 [2021-01-02, 2021-02-05]	2020-10-15 [2020-08-12, 2021-01-03]	0.256
First vaccination : n (%)	391	0	42 (10.74%)	1 (5.56%)	0 (0.00%)	2 (6.25%)	39 (11.75%)	0.456
Vaccine 1 company : n (%)	42	349						
<i>BioNTech / Pfizer</i>			17 (40.48%)	1 (100.00%)	-	0 (0.00%)	16 (41.03%)	
<i>Moderna</i>			8 (19.05%)	0 (0.00%)	-	2 (100.00%)	6 (15.38%)	
<i>Oxford / AstraZeneca</i>			17 (40.48%)	0 (0.00%)	-	0 (0.00%)	17 (43.59%)	
Second vaccination : n (%)	391	0	23 (5.88%)	1 (5.56%)	0 (0.00%)	2 (6.25%)	20 (6.02%)	0.900
Vaccine 2 company : n (%)	23	368						
<i>BioNTech / Pfizer</i>			15 (65.22%)	1 (100.00%)	-	0 (0.00%)	14 (70.00%)	
<i>Moderna</i>			7 (30.43%)	0 (0.00%)	-	2 (100.00%)	5 (25.00%)	
<i>Oxford / AstraZeneca</i>			1 (4.35%)	0 (0.00%)	-	0 (0.00%)	1 (5.00%)	
Vaccinated and infected : n (%)	391	0	73 (18.67%)	4 (22.22%)	0 (0.00%)	3 (9.38%)	66 (19.88%)	0.225
Follow-up Ag-RTD at 6 days : n (%)	391	0						0.069
<i>Negative result</i>			344 (87.98%)	17 (94.44%)	6 (66.67%)	31 (96.88%)	290 (87.35%)	
<i>Not attending</i>			47 (12.02%)	1 (5.56%)	3 (33.33%)	1 (3.12%)	42 (12.65%)	
Extra tests at 14 days	18	373						-
<i>PCR</i>			13 (72.22%)	-	2 (100.00%)	2 (100.00%)	9 (64.29%)	
<i>TAR</i>			5 (27.78%)	-	0 (0.00%)	0 (0.00%)	5 (35.71%)	
Test results at 14 days	18	373						-
<i>Negative result</i>			18 (100.00%)	-	2 (100.00%)	2 (100.00%)	14 (100.00%)	

## DISCUSSION

The 'Reobrim Sitges' nightlife study loosening alarm state restrictions in small clubs resulted in no positive SARS-CoV-2 test results among participants at the 14 days follow-up, while in the control group 2 positive cases were detected without statistically significant differences. This study adds new evidence to the other studies assessing the impact of the reopening of the social and cultural nightlife.

Up to date, most of articles studying COVID-19 in mass-gathering events either reported retrospective analyses of SARS-CoV-2 transmission [19–21] or described mitigation plans and measures applied during mass-gathering events [22,23]. Only one controlled trial was published in Catalonia [13].

Revollo et al. [13] present a randomized controlled trial assessing the impact, in terms of SARS-CoV-2 infections, of attending a live gig in a medium-sized concert hall (capacity of 900 people) in Barcelona, on December 2020. 1047 individuals aged 18-59 years with a negative Ag-RDT on the same day, no comorbidities, and declaring not having a positive COVID-19 diagnose during the last 14 days were randomly assigned to the experimental group and attended the indoor event (at 50% of hall's capacity; n=465), or sent home (control group, n=495). With a mean staying time of 2:40 hours, 8 days after the event no positive RT-PCR tests were found in the intervention group, whereas two (<1%) individuals in the control arm had a positive Ag-RDT and RT-PCR results. Common elements with our study are: sample size, use of Ag-RDT as inclusion criteria, age ranges, freedom of movement with no social distance, and use of masks (although both FFP2 and quirurgical were allowed in our study). Both studies obtained similar results, despite in ours a) drinking was allowed in all the perimeter, and b) the event was developed in locals with indoor capacities below 100 people without indoor air quality control, and with bigger outdoor areas.

On March 2021 an observational study assessed the impact of attending to a live gig in a big concert hall in Barcelona: 4.584 attendees (below 30% of 17,000 persons hall's capacity) with negative Ag-RDT simultaneously enjoyed the experience in three isolated groups, with no social distancing, wearing FFP2 masks and independent drinking areas, resulting in a cumulative incidence at 14 days of 130.7 infections per 100,000 inhabitants. This, compared to the age-adjusted estimation of 295.5/100,000 observed in the city of Barcelona for the same period, supposed no significant impact due to the event [14], in line with our results.

As aforementioned, the press has published other experiences such as the "Obrir Girona" initiative [15], performed from April 23rd to May 22nd 2021 in Girona, assessing the impact of reactivating a broader range of social activities under "very low infection capacity" conditions. Social activities included dinners in restaurants, an electronic music gig (250 attendees at full capacity, wearing masks -drinking allowed in independent room- with no social distance), and a pop gig (1,000 attendees at 56% capacity, wearing masks -drinking allowed at exterior bar-with no social distance). "Very low infection capacity" was considered if participants were vaccinated in the last 6 months, had overcome COVID-19 in the last 3 months, or had a negative Ag-RDT in the last 36 hours. Of the 1,350, only 3 participants got a positive test between day 7 and 14 after the events [24]. Remarkably, the study inclusion criteria of participants relied not only on Ag-RDT screening, but also considered recent vaccination or

1  
2  
3 infection as an indicator of low infection capacity. Despite its heterogeneity in social activities  
4 and locations, the observed low incidence rate supports their low infection capacity criterium.  
5

6  
7 Other projects have been developed in Netherlands and United Kingdom to examine how  
8 events can be reopened with reduced risk [25,26]. A pilot study in Liverpool explored the  
9 nightclubs reopening in semi-controlled settings [27]. Despite differences in the methodology,  
10 results were in line with ours; an exploratory modelling of transmission risks at nightclubs  
11 suggests that primary transmissions are reduced by 53% through testing on the day.  
12

13  
14 Informally, if these unpublished results are right, social activities in Catalonia under sanitary  
15 controlled access would have resulted in 9 people infected at 14 days out of 6739 participants  
16 up to date. However, press information has attributed to the three extraordinarily authorized  
17 festivals in Catalonia on July 2021 a risk of infection around 1.7 times higher than expected  
18 [28,29]; without a published official report, the press conference of the government public  
19 health agency pointed out the inefficiency of the Ag-RDT control process in one of the events,  
20 and the relaxation in the use of masks after several hours in a considered safe environment,  
21 along with the apparition of more contagious SARS-CoV-2 variants, as possible causes for  
22 such bad results in comparison to pilot studies. This led to new limitations and highlighted the  
23 importance of vaccination and the cumulative protective effect of Ag-RDT tests and masks in  
24 these scenarios.  
25  
26

27  
28 On July 29th, after few weeks of alarming negative evolution, specially in the 15-24 age range  
29 population, the Catalan government decided to suppress the reopening of nightlife social  
30 activities [30]. The opening of such activities had been done until then without any sanitary  
31 access control, exclusively with mandated use of masks. The dissonance between results of  
32 controlled studies and real life, apart from the higher transmissibility of the delta variant,  
33 highlights the importance of this access control and sanitary measures when reducing the  
34 spreading of the virus.  
35  
36

37  
38 Despite Ag-RDT lacks in high sensitivity [9] evidence supports its use, along with other  
39 measures, to ensure safe enough environments for mass-gathering (nightlife) events; a low-  
40 cost, easy performance and quick-result test seems a good option for a wide range of social  
41 activities. Nonetheless, the use of Ag-RDT test needs to be evaluated in every situation  
42 depending on the type of activitie and the epidemiological data at the time of the event,  
43 including rate of vaccination [31]. Each real situation needs to balance the benefits of having  
44 rapid Ag-RDT results for immediate and appropriate management and public health action  
45 against the harm of false negative results [31]. In our study, as the two studies in Barcelona,  
46 the organization provided the tests the same day. This guarantees the temporal proximity to  
47 the event and the inalterability of results, but requires a logistic, sanitary and economic effort  
48 which could be assumable for large events but hardly for small clubs' nightlife. Moreover,  
49 performing tests does not exclude the necessity to follow other security measures, as the use  
50 of the mask [26]. Applications in line with the "Re-open EU" or the one used in the "Obrir  
51 Girona" study can be a useful tool for reporting low infection capacity probable from different  
52 sources.  
53  
54  
55

56  
57 The highly variable context/situation hinders the reproducibility of these types of studies. The  
58 extension of vaccination to all age ranges along with sanitary access control to nightlife  
59 activities should provide a safer nightlife enviroment, necessary to recover social and  
60

1  
2  
3 economic activities, while to disencouraging uncontrolled nightlife “botellón” (street alcohol  
4 consumption) and ilegal private massive events.  
5

6  
7 During our study, the first cases of SARS-CoV-2 Delta variant had been detected in Spain;  
8 this variant seems to be around 60% more transmissible than the Alpha variant. Thus, Delta  
9 variant is spreading worldwide as the fittest and fastest variant and it is becoming dominant in  
10 many countries. Evidence in the UK shows that 75% of infections by Delta variant are  
11 occurring in people who are not vaccinated and about 4 to 57% in people who are fully  
12 vaccinated [32], thus affecting age ranges more prone to enjoy nightlife. More research is  
13 needed to ensure our results can be extrapolated to the Delta variant.  
14  
15

16 Some limitations are present in our study. The selection of volunteers was non-random, with  
17 the aim of including a profile of clients specific of each nightclub. To adjust for this selection  
18 bias, a control group matched by age, sex, and socioeconomic index, history of previous  
19 SARS CoV-2 infection, and SARS CoV-2 vaccine status was sought. However, a residual bias  
20 cannot be ruled out as a result of other parameters that we cannot control.  
21  
22

23 On the other hand, monitoring new infections through EHR may not have detected  
24 asymptomatic or mild symptomatic cases that were not consulted by health systems. This fact  
25 was minimized in the intervention group with the performance of the Ag-RDT follow-up test 6  
26 days after the intervention, with an acceptable loss rate of 12%. Despite the lower sensitivity  
27 and specificity of the Ag-RDT test, this follow-up increased the likelihood of measuring the  
28 impact of the intervention on the onset of new infections, at risk of overestimating the negative  
29 impact of the intervention.  
30  
31

32 As a conclusion, in our study the attendance to nightclubs under controlled conditions and  
33 previous negative Ag-RDT did not show an increased transmissibility of SARS-CoV-2. These  
34 results, within the framework of health and safety, provide insight into the possibility of more  
35 secure apertures for event organizers.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ACKNOWLEDGMENTS

We would like to thank Carles Cortés, Eva Lacasta, David Alburquerque, Mercè Fernandez and the whole team of Ajuntament de Sitges (Sitges City Council) that made it possible, Damià Orts and the Associació d'Establiments d'Oci Nocturn de Sitges (Association of Nightlife Premises of Sitges) and Glòria Cabrera and the Federació Catalana de Locals d'Oci Nocturn (Catalan Federation of Nightclubs) for the counseling in the design of the study and dissemination, and Esther Sancho and the whole Curasana team.

## DECLARATION OF INTERESTS

The authors declare no conflict of interest.

## FUNDING

The Sitges Council funded the initiative (covering all test, organization and security costs), relying on the Catalan Public Health Agency to develop it. Award/Grant number is not applicable.

They did not intervene in the analysis, discussion or publications of results.

## CONTRIBUTORS

OC: Study design, data analysis and manuscript elaboration. SC: Study design and manuscript elaboration. MM: Study design and manuscript elaboration. DL: Study design and manuscript elaboration. MA: Study design, data extraction and manuscript revision. JA: Study design and manuscript elaboration. JC: Conception, study design and manuscript revision. JB: Conception, study design and manuscript revision. BS: Conception, study design and manuscript elaboration. All authors have approved the final version of the manuscript.

## REFERENCES

- 1 Johns Hopkins University. Center for Systems Science and Engineering (CSSE). Coronavirus COVID-19 (2019-nCoV). <https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6> (accessed 13 Aug 2021).
- 2 Jayaweera M, Perera H, Gunawardana B, *et al.* Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. *Environ Res* 2020;**188**:109819. doi:10.1016/J.ENVRES.2020.109819
- 3 Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. *Ann Intern Med* 2020;**173**:362–7. doi:10.7326/M20-3012
- 4 Somsen GA, van Rijn C, Kooij S, *et al.* Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. *Lancet Respir Med* 2020;**8**:658. doi:10.1016/S2213-2600(20)30245-9
- 5 World Health Organization. Coronavirus disease (COVID-19). 2020.<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19> (accessed 13 Aug 2021).
- 6 Lauer S, Grantz K, Bi Q, *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med* 2020;**172**:577–82. doi:10.7326/M20-0504
- 7 Wang W, Xu Y, Gao R, *et al.* Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* 2020;**323**:1843. doi:10.1001/JAMA.2020.3786
- 8 Younes N, Al-Sadeq DW, Al-Jighefee H, *et al.* Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. *Viruses* 2020;**12**:582. doi:10.3390/v12060582
- 9 World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. 2020.<https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays> (accessed 13 Aug 2021).
- 10 Mina MJ, Peto TE, García-Fiñana M, *et al.* Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19. *Lancet* Published Online First: 17 February 2021. doi:10.1016/S0140-6736(21)00425-6
- 11 Ministerio de la Presidencia R con las C y MD. Real Decreto 463/2020, de 14 de marzo, por el que se declara el estado de alarma para la gestión de la situación de crisis sanitaria ocasionada por el COVID-19. 2020. <https://www.boe.es/buscar/pdf/2020/BOE-A-2020-3692-consolidado.pdf> (accessed 13 Aug 2021).
- 12 Departament de Salut. Generalitat de Catalunya. Dades COVID VACUNACIÓ. 2021.<https://dadescovid.cat/vacunacio/> (accessed 13 Aug 2021).
- 13 Revollo B, Blanco I, Soler P, *et al.* Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. *Lancet* Published Online First: 2021. doi:10.1016/S1473-3099(21)00268-1
- 14 Llibre JM, Videla S, Clotet B, *et al.* Screening for SARS-CoV-2 Antigen Before a Live Indoor Music Concert: An Observational Study. *Ann Intern Med* Published Online First: 20 July 2021. doi:10.7326/M21-2278
- 15 Centre Blockchain de Catalunya. Obrir Girona – CBCat. 2021.<https://obrirgirona.cat/> (accessed 13 Aug 2021).



- 1  
2  
3 16 Generalitat de Catalunya. Departament de Salut. Procediment d'actuació enfront de  
4 casos d'infecció pel nou coronavirus SARS-CoV-2 Sub-direcció General de Vigilància  
5 i Resposta a Emergències de Salut Pública. 2021.  
6 [https://canalsalut.gencat.cat/web/.content/\\_A-Z/C/coronavirus-2019-ncov/material-](https://canalsalut.gencat.cat/web/.content/_A-Z/C/coronavirus-2019-ncov/material-)  
7 (accessed 13 Aug 2021).  
8
- 9 17 Gobierno de España. Ministerio de Sanidad. Estrategia de detección precoz,  
10 vigilancia y control de COVID-19 . 2021.  
11
- 12 18 Domínguez-Berjón MF, Borrell C, Cano-Serral G, *et al.* [Constructing a deprivation  
13 index based on census data in large Spanish cities(the MEDEA project)]. *Gac Sanit*  
14 2008;**22**:179–87. doi:10.1157/13123961  
15
- 16 19 Mat NFC, Edinur HA, Razab MKAA, *et al.* A Single Mass Gathering Resulted in  
17 Massive Transmission of COVID-19 Infections in Malaysia with Further International  
18 Spread. *J Travel Med* 2020;**27**. doi:10.1093/JTM/TAAA059  
19
- 20 20 Pavli A, Smeti P, Papadima K, *et al.* A cluster of COVID-19 in pilgrims to Israel. *J*  
21 *Travel Med* 2020;**27**:1–3. doi:10.1093/JTM/TAAA102  
22
- 23 21 Shmuel K, Dalia M, Tair L, *et al.* Low pH Hypromellose (Taffix) nasal powder spray  
24 could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly  
25 endemic community: an observational prospective open label user survey. *Expert Rev*  
26 *Anti Infect Ther* 2021;:1. doi:10.1080/14787210.2021.1908127  
27
- 28 22 Limbachia J, Owens H, Matean M, *et al.* Organizing a Mass Gathering Amidst a  
29 Rising COVID-19 Public Health Crisis: Lessons Learned From a Chinese Public  
30 Health Forum in Vancouver, BC. *Cureus* Published Online First: 29 December 2020.  
31 doi:10.7759/cureus.12365  
32
- 33 23 McCloskey B, Zumla A, Ippolito G, *et al.* Mass gathering events and reducing further  
34 global spread of COVID-19: a political and public health dilemma. *Lancet*  
35 2020;**395**:1096. doi:10.1016/S0140-6736(20)30681-4  
36
- 37 24 Agència Catalana de Notícies. Els impulsors d'Obrir Girona demanen ampliar el  
38 programa a tot Catalunya després de l'èxit de la prova - Diari de Girona.  
39 2021.[https://www.diaridegirona.cat/girona/2021/06/04/els-impulsors-dobrir-girona-](https://www.diaridegirona.cat/girona/2021/06/04/els-impulsors-dobrir-girona-demanen-52621652.html)  
40 [demanen-52621652.html](https://www.diaridegirona.cat/girona/2021/06/04/els-impulsors-dobrir-girona-demanen-52621652.html) (accessed 13 Aug 2021).  
41
- 42 25 Dutch government. Fieldlab Evenementen.  
43 2020.<https://fieldlabevenementen.nl/fieldlab-english/> (accessed 13 Aug 2021).  
44
- 45 26 Gov.UK. Information on the Events Research Programme - GOV.UK.  
46 2021.[https://www.gov.uk/government/publications/information-on-the-events-](https://www.gov.uk/government/publications/information-on-the-events-research-programme)  
47 [research-programme](https://www.gov.uk/government/publications/information-on-the-events-research-programme) (accessed 13 Aug 2021).  
48
- 49 27 Department for Digital Culture Media and Sport - Gov.UK. Events Research  
50 Programme: Phase I findings - GOV.UK.  
51 2021.[https://www.gov.uk/government/publications/events-research-programme-](https://www.gov.uk/government/publications/events-research-programme-phase-i-findings/events-research-programme-phase-i-findings)  
52 [phase-i-findings/events-research-programme-phase-i-findings](https://www.gov.uk/government/publications/events-research-programme-phase-i-findings/events-research-programme-phase-i-findings) (accessed 13 Aug  
53 2021).  
54
- 55 28 Mouzo J. Los festivales de música en Cataluña aumentaron la transmisión de la  
56 covid: más de 2.000 asistentes se infectaron. El País.  
57 2021.[https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-](https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-infectaron.html)  
58 [cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-](https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-infectaron.html)  
59 [infectaron.html](https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-infectaron.html) (accessed 13 Aug 2021).  
60
- 61 29 Cabezas C. Roda de premsa sobre el seguiment del procés de vacunació de la  
62 COVID-19 a Catalunya.

- 1  
2  
3 2011;;31:55.<https://www.youtube.com/watch?v=9MUfakIxVSA&t=1915s> (accessed 13  
4 Aug 2021).  
5  
6 30 Diari Oficial de la Generalitat de Catalunya. RESOLUCIÓ SLT/2498/2021. Barcelona:  
7 : Generalitat de Catalunya 2021. [https://dogc.gencat.cat/ca/document-del-](https://dogc.gencat.cat/ca/document-del-dogc/?documentId=907691)  
8 [dogc/?documentId=907691](https://dogc.gencat.cat/ca/document-del-dogc/?documentId=907691) (accessed 13 Aug 2021).  
9  
10 31 Peeling RW, Olliaro PL, Boeras DI, *et al.* Scaling up COVID-19 rapid antigen tests:  
11 promises and challenges. *Lancet Infect Dis* Published Online First: 2021.  
12 doi:10.1016/S1473-3099(21)00048-7  
13 32 Public Health England. SARS-CoV-2 variants of concern and variants under  
14 investigation in England. Technical Briefing 15. 2021.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
<b>Title and abstract</b>			
Title	<a href="#">#1a</a>	Indicate the study's design with a commonly used term in the title or the abstract	3
Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background / rationale	<a href="#">#2</a>	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	<a href="#">#3</a>	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	<a href="#">#4</a>	Present key elements of study design early in the paper	5
Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant dates, including periods	5-6

1		of recruitment, exposure, follow-up, and data collection		
2	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.	5-6
3				
4				
5				
6	Eligibility criteria	<a href="#">#6b</a>	For matched studies, give matching criteria and number of exposed and unexposed	6
7				
8				
9				
10	Variables	<a href="#">#7</a>	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
11				
12				
13				
14				
15	Data sources /	<a href="#">#8</a>	For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. Give information separately for for exposed and unexposed groups if applicable.	6
16	measurement			
17				
18				
19				
20				
21				
22	Bias	<a href="#">#9</a>	Describe any efforts to address potential sources of bias	6
23				
24	Study size	<a href="#">#10</a>	Explain how the study size was arrived at	6
25				
26				
27	Quantitative	<a href="#">#11</a>	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	6
28	variables			
29				
30				
31	Statistical	<a href="#">#12a</a>	Describe all statistical methods, including those used to control for confounding	
32	methods			
33				
34	6			
35				
36				
37	Statistical	<a href="#">#12b</a>	Describe any methods used to examine subgroups and interactions	6
38	methods			
39				
40				
41	Statistical	<a href="#">#12c</a>	Explain how missing data were addressed	6
42	methods			
43				
44	Statistical	<a href="#">#12d</a>	If applicable, explain how loss to follow-up was addressed	NA
45	methods			
46				
47				
48	Statistical	<a href="#">#12e</a>	Describe any sensitivity analyses	
49	methods			
50				
51				
52	NA			
53				
54	<b>Results</b>			
55				
56				
57	Participants	<a href="#">#13a</a>	Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible,	7
58				
59				
60				

included in the study, completing follow-up, and analysed. Give information separately for for exposed and unexposed groups if applicable.

1			
2			
3			
4			
5	Participants	<a href="#">#13b</a>	Give reasons for non-participation at each stage 7
6			
7	Participants	<a href="#">#13c</a>	Consider use of a flow diagram
8			
9	NA		
10			
11			
12	Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg demographic, clinical, 7-8 social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.
13			
14			
15			
16			
17			
18			
19	Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing data for each variable of interest
20			
21			
22			
23	8		
24			
25	Descriptive data	<a href="#">#14c</a>	Summarise follow-up time (eg, average and total amount)
26			
27			
28	7		
29			
30	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable.
31			
32			
33			
34			
35	8		
36			
37			
38	Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 8
39			
40			
41			
42			
43			
44	Main results	<a href="#">#16b</a>	Report category boundaries when continuous variables were categorized NA
45			
46			
47			
48	Main results	<a href="#">#16c</a>	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
49			
50			
51			
52	7		
53			
54			
55	Other analyses	<a href="#">#17</a>	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses NA
56			
57			

## Discussion

1	Key results	<a href="#">#18</a>	Summarise key results with reference to study objectives	9
2				
3	Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into account sources of	11
4			potential bias or imprecision. Discuss both direction and magnitude of	
5			any potential bias.	
6				
7				
8	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation considering objectives,	11
9			limitations, multiplicity of analyses, results from similar studies, and	
10			other relevant evidence.	
11				
12				
13	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external validity) of the study results	10-11
14				
15				
16	<b>Other</b>			
17	<b>Information</b>			
18				
19				
20	Funding	<a href="#">#22</a>	Give the source of funding and the role of the funders for the present	12
21			study and, if applicable, for the original study on which the present	
22			article is based	
23				
24				

25 The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY.  
 26 This checklist was completed on 05. October 2021 using <https://www.goodreports.org/>, a tool made by the  
 27 [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60

# BMJ Open

## Black box study with a paired control group to evaluate the reopening of nightlife during COVID-19 pandemic: 'Reobrim Sitges'

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058595.R1
Article Type:	Original research
Date Submitted by the Author:	29-Dec-2021
Complete List of Authors:	Cunillera Puértolas, Oriol; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona Contreras-Martos, Sara; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona Marzo-Castillejo, Mercè; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona López Gallegos, Darío; Institut Català De La Salut, Servei d'Atenció Primària Alt Penedès-Garraf-Baix Llobregat Nord, Direcció d'Atenció Primària Costa de Ponent Acedo Anta, Mateo; Institut Català de la Salut, Secretaria Tècnica, Direcció d'Atenció Primària Costa de Ponent; Universitat de Barcelona Facultat de Medicina i Ciències de la Salut, Escola d'Infermeria Almeda Ortega, Jesús; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona Colom, Joan; Agència de Salut Pública de Catalunya, Sub-direcció General de Drogodependències Basora, Josep; IDIAP Jordi Gol, Institut Universitari d'Investigació en Atenció Primària Salvador-Gonzalez, Betlem; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Epidemiology, Infectious diseases, Public health
Keywords:	COVID-19, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Public health < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 *Black box study with a paired control group to evaluate the reopening of nightlife during*  
5 *COVID-19 pandemic: 'Reobrim Sitges'*  
6

7 Oriol Cunillera Puértolas<sup>1,2</sup>

8 Sara Contreras-Martos<sup>1,2,3</sup>

9 Mercè Marzo- Castillejo<sup>1,2,3</sup>

10 Darío López Gallegos<sup>4</sup>

11 Mateo Acedo Anta<sup>5,6</sup>

12 Jesús Almeda Ortega<sup>1,2,3</sup>

13 Joan Colom Farran<sup>7</sup>

14 Josep Basora i Gallisà<sup>8</sup>

15 Betlem Salvador-González<sup>1,3</sup>

16  
17  
18  
19  
20  
21 1-Unitat de Suport a la Recerca Costa de Ponent, Fundació Institut Universitari per a la recerca a  
22 l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Cornellà de Llobregat, Spain

23  
24 2-Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain.

25  
26 3-Unitat de Suport a la Recerca, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la  
27 Salut, L'Hospitalet de Llobregat, Spain

28  
29 4-Servei d'Atenció Primària Alt Penedès-Garraf-Baix Llobregat Nord, Direcció d'Atenció Primària Costa  
30 de Ponent, Institut Català de la Salut, L'Hospitalet de Llobregat, Spain.

31  
32 5-Secretaria Tècnica, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la Salut, Cornellà  
33 de Llobregat, Spain.

34  
35 6-Escola d'Infermeria, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona,  
36 Spain

37  
38 7-Subdirecció General de Drogodependències. ASPCAT. Departament de Salut, Generalitat de  
39 Catalunya, Barcelona, Spain.

40  
41 8-Institut Universitari d'Investigació en Atenció Primària (IDIAP Jordi Gol), Barcelona, Spain.

42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53 \* *Corresponding author:* Betlem Salvador-González

54 C/ Bellaterra, 41, 1er pis 08940 Cornellà de Llobregat, Barcelona. [bsalvador@ambitcp.catsalut.net](mailto:bsalvador@ambitcp.catsalut.net)

55  
56 Word count: 3230 words  
57  
58  
59  
60

## ABSTRACT

Background: The economic impact of governmental legal restrictions during COVID-19 pandemic requires evaluation of the balance between health and economy. This study aims to assess the health impact of reopening nightlife under controlled conditions.

Objectives: To assess the impact of loosening alarm state restrictions in small clubs nightlife on SARS-CoV-2 infections at 14 days.

Design: Black box study with a paired control group (1:5 ratio)

Setting: A nightlife restricted area in Sitges on 20st May 2021. 5 nightclubs with interior areas and exterior terraces. Wearing masks was mandatory, drinking was allowed, and social distance was not required.

Participants: Volunteers were selected through a convenience sampling. Participants, aged over 17, with negative Ag-RDT test on the same afternoon, and without a positive RT-PCR or Ag-RDT test and/or symptoms associated with COVID-19 in the last 7 days, not being close contact with someone infected in the last 10 days, or having had close contact with someone with a suspicion of COVID-19 in the last 48 hours was required to access the event.

Primary outcome: Evidence of infection at electronic health records by SARS-CoV-2 at 14 days follow-up.

Results: Of the 391 participants (median age 37 years; 44.3% women), no positive SARS-CoV-2 cases were detected at 14 days, resulting in an estimation of a cumulative incidence (95% confidence interval) of 0 (0, 943) /100,000 inhabitants. In the control group, 2 cases with RT-PCR test were identified, a cumulative incidence of 102.30 (12.4, 369) /100,000 inhabitants.

Conclusions: Attendance to nightlife under controlled conditions and previous negative Ag-RDT did not show an increased transmissibility of SARS-CoV-2. Secure aperture of nightlife sector is possible under reduced capacity limits, controlled access by Ag-RDT, and environments where compliance of sanitary measures conditions are maintainable.

### Strengths and limitations of this study

- This is a black box study with a convenience sampling, with a paired control group.
- Participants performed Ag-RDT tests the afternoon of the event's day prior accessing the event
- Evidence of infection by SARS-CoV-2 at 14 days was obtained in the EHR
- Ag-RDT follow-up tests 6 days after the intervention minimized unregistered infections in the exposed group with only 12% loss.

## INTRODUCTION

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic had infected 186 million people and caused over 4 million deaths worldwide by July 12<sup>th</sup> 2021, with wide variability between countries and regions [1]. The SARS-CoV-2 transmission mostly occurs by direct contact or through droplets and aerosols from an infected person located within 2 meters range and exposition times over 15 minutes [2,3]. Indoor, poorly ventilated, crowded spaces [4] where people gather are hotspots for the transmission of virus [5].

The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, has an incubation period that varies from 2 to 14 days. Among the symptomatic people, 50% develop symptoms within 5.1 days and 75% within 11.5 days [6].

The gold standard diagnostic test for SARS-Cov-2 is the real-time reverse-transcription polymerase chain reaction (RT-PCR), which detects viral RNA, presenting good results in terms of reliability, sensibility and specificity [7]. Although RT-PCR can detect positive cases from the beginning of the infection in symptomatic and asymptomatic people, the need for well-equipped labs with specialized professionals increases the total delivery times and costs [8]. In contrast, the lateral flow immunochromatographic rapid antigen diagnostic tests (Ag-RDT) for SARS-CoV-2 can detect viral proteins and provide results *in situ* within less than 30 minutes. Despite its sensitivity is below WHO's recommendations, Ag-RDTs still offer the possibility of rapid, easy and inexpensive detection of SARS-CoV-2 in individuals who have high viral loads and hence are at high risk of transmitting the infection to others [9], which is the relevant issue for most public health measures [10].

The sanitary and social crisis subsequent to the COVID-19 pandemic have forced many governments to deploy new social policies and legal restrictions, mostly focused on reducing the spreading of COVID-19. In Spain, restrictions to mobility and economic activity -with temporal closure of restaurants, hotels and nightlife activities - began with the first alarm state on March 2020 [11]. At the moment of writing this paper, September 2021, some restrictions on capacity limitations and opening hours still prevail. The balance between health and economy is still on study in the more flexible stage we are in: bars, restaurants, pubs, discotheques, and concert venues were still on the tightrope, claiming for secure measures allowing them to flounder.

The herd-immunity, mainly through massive vaccination, is the key goal to restore social and economic activities in this sector. In Catalunya, on May 5th 2021, a 30.5% of the population had received at least one dose, and a 13.6% had completed vaccination [12]. Due to age prioritisation, only 6.9% of 18-24 years old Catalans and 11% of aged 25-49 had some vaccination, thus constituting age ranges where legal measures were still prominent on controlling virus transmission.

Some studies have been carried out in Catalunya to assess the impact of losing legal restrictions on various types of social activities, including indoor gigs and dining passes in restaurants; although just two articles have been published up to date [13,14], press conferences have spread some results on three initiatives [15]. None of these studies detected any increased risk associated with the expositions.

The present study is another step in generating evidence on the safety reopening of social activities in Catalonia. We aimed to assess the impact of loosening alarm state restrictions in small clubs nightlife on SARS-CoV-2 infections at 14 days.

## METHODS

This is a black box study with a paired control group, performed in a nightlife-restricted area in Sitges (Barcelona, Spain) on May 20th 2021.

The volunteer attending the event were recruited by convenience sampling promoted -mainly through social networks- by participant entities (council, guild, locals) and registered through the official city council web. Inclusion and exclusion criteria for all exposition groups (formed by study volunteers and staff groups) are defined in table 1. Participants performed their Ag-RDT tests in scheduled intervals the afternoon of the event's day in Sitges. The Ag-RDT test was performed by trained health professionals following manufacture's instructions (AllTest, Ref. ICOV-502, Japan). Manufacturers' reported sensitivity and especificity were 96.4% and 99.9%, respectively.

**Table 1.** Inclusion and exclusion criteria for study participants (volunteers and staff groups) attending the nightlif mass-gathering event

Inclusion criteria	Exclusion criteria
1. Aged over 17	1. Declaring to have a positive RT-PCR or Ag-RDT test in the last 7 days
2. Living in Sitges area and Barcelona	2. Presenting symptoms associated with COVID-19 in the last 7 days (according to Catalan Health Department protocols [16,17]):
3. Having an individual health card of the Catalan public healthcare system	a) <i>at least one of these: fever, persistent cough, shortness of breath, anosmia, ageusia</i>
4. A negative Ag-RDT test the same afternoon (provided by the organization)	b) <i>at least two of the following: sore throat, a cold, fatigue, myalgia, headache, vomiting or diarrhea stomach ache</i>
	3. Having had close contact with someone infected in the last 10 days
	4. Having had close contact with someone with a suspicion of COVID-19 in the last 48 hours

The nightlife event was developed from 23:00 p.m. of May 20th to 3:00 a.m of May 21st, in a restricted street section, including 5 nightclubs with interior areas (capacity 42-98 people) and exterior terraces (capacity 15-35 people), with controlled registered access exclusively for participants. Mask was mandatory (quirurgical or FFP2), except for drinking or smoking.

1  
2  
3 Drinking was allowed indoors and outdoors. Social distance was not required. Hydroalcoholic  
4 gel and panels reminding COVID-19 safety standards and their participation in the study were  
5 distributed throughout all the area. No special ventilation measures were required. A follow-  
6 up Ag-RDT test on day 6 after the event was performed on participants.  
7

8  
9 The control group was obtained through secondary data from the primary care electronic  
10 health records (PC-EHR), by a pseudonymized paired extraction of individuals not attending  
11 the social event. Pairing was executed by exact age, sex, residence municipality,  
12 socioeconomic index, previous SARS-CoV-2 confirmed infection, and vaccination status (at  
13 least one dose administered), by a 1:5 ratio.  
14

15  
16 Sample size was conditioned on capacity limitations fixed on 75% of the locals' usual limits  
17 (according to and authorized by the Health Department within the context of this study),  
18 resulting in 400 volunteers. Considering the 14 days cumulative incidence of COVID-19  
19 occurring in the health district (Gerència Territorial Metropolitana Sud) on April 29th 2021  
20 (210/100,000 inhabitants [<https://dadesocovid.cat/>]), significant differences would be found  
21 observing a 14 days incidence in the intervention group of 1.38% (6 positive cases), with a  
22 level of significance of 0.05 and power of 0.8.  
23  
24

## 25 **Variables**

26  
27 The main outcome was confirmed case (PCR, Ag-RDT and serology) of SARS-CoV-2  
28 infection at 14 days follow-up. As a secondary outcome, the number of positive Ag-RDTs  
29 performed in-person at 6 days in the exposition group was considered. The main outcome  
30 was gathered from both the 6 days follow-up Ag-RDT and any registry in the PC-EHR at 14  
31 days follow-up for the exposition group, an only from PC-EHR for the control group.  
32  
33

34  
35 All other variables were obtained from PC-EHR: age, sex, MEDEA socioeconomic deprivation  
36 index [18] (classifying individuals into septiles), previous SARS-CoV-2 confirmed infection  
37 and previous vaccination: first and second intake, date, and vaccine commercial brand  
38 (BioNTech - Pfizer / Moderna / Oxford AstraZenecae/Janssen-Johnson&Johnson).  
39

40  
41 This information was collected for all participants, which were categorized according to their  
42 role as Organizers, Security personnel, Club workers, or Volunteers.  
43

## 44 **Statistical analysis**

45  
46 All variables were described and compared by participant role groups. Median, interquartile  
47 range, mean and standard deviation were calculated for continuous variables, and absolute  
48 and relative frequencies were described for categorical variables. Homogeneity in distribution  
49 across roles was tested using Kruskal-Wallis or Chi-square tests and complete case analysis.  
50 As pairing was performed by the exact characteristics, no description will be provided for the  
51 controls (presenting the same values as study participants).  
52  
53

54  
55 Cumulative incidence was calculated for study participants as the number of positive cases at  
56 14 days divided by the total of individuals exposed, transformed into cases per 100,000  
57 inhabitants, and with confidence intervals estimated by the exact method.  
58

## 59 **Patient and Public Involvement**

1  
2  
3 The Associació d'Establiments d'Oci Nocturn de Sitges (Association of Nightlife Premises of  
4 Sitges) and the Federació Catalana de Locals d'Oci Nocturn (Catalan Federation of  
5 Nightclubs) proposed and promoted the initiative and developed with The Sitges Council the  
6 initial proposal. The Catalan Public Health Agency was contacted to adapt it to a formal study  
7 design and develop it, with the aforementioned entities participating in the conception and  
8 dissemination. There was an immediate return of results to the entities to allow their  
9 dissemination  
10  
11

### 12 **Ethical considerations**

13  
14 This study was approved by the Research Ethics Committee of the Institute for Primary Health  
15 Care Research Jordi Gol i Gurina (IDIAPJGol) and the Technical Committee of the Civil  
16 Protection Plan of Catalonia (PROCICAT). The study guarantees compliance with the new  
17 General Data Protection Regulation (GDPR) EU 2016/679, the guidelines of the Principles of  
18 the Declaration of Hèlsinki and the Belmont Report.  
19

20  
21 Participants were informed about the project and signed a responsible statement and informed  
22 consent to participate and allowed the use of their pseudonymized data exclusively for this  
23 project. Informed consent was not required for participants in the control group as the  
24 information was pseudonymized.  
25

26 The external entity 'Curasana' ([www.curasana.org](http://www.curasana.org)) was responsible for the logistic and  
27 performance of Ag-RDT tests. Results were sent to the Catalan Institute of Health (ICS);  
28 positive results were communicated and introduced to EHR for assistance purposes. The ICS  
29 and the IDIAPJGol were independently responsible for the data processing within the  
30 framework of this study.  
31  
32

### 33 **RESULTS**

34  
35  
36 No positive Ag-RDTs tests were detected at baseline. The final exposition group was  
37 composed of 391 participants (332 volunteers, 9 security staff, 32 bartenders/DJs, 18  
38 organizers) that accessed the nightlife-restricted area. Participants had a median/mean age  
39 of 37/37.5 years, 50% were between 23 and 50 years (Table 2). 55.8% (n=218) were male,  
40 and there was an underrepresentation of extreme Catalan socioeconomic ranges (specially  
41 the least deprived, with a 4.1% in front of the 28.6% in general population). About 9.0% (n=35)  
42 had been previously infected by SARS-CoV-2, 10.7% (n=42) had at least one vaccination  
43 dose, and 19.7% (n=73) had been both vaccinated and infected.  
44  
45

46  
47 Staff groups were significantly different from volunteers in terms of age (organizers were  
48 significantly older), sex (due to a 100% male security personnel) and socioeconomic status  
49 (55.5% -5- of security personnel came from most deprived areas). Although not significant,  
50 security personnel and bartenders/DJs had lower percentages of vaccination and previous  
51 infection. As control group was matched by exact characteristics, it presented the exact same  
52 distribution for all variables except for the outcomes.  
53  
54

55  
56 Volunteers stayed in the local nightlife delimited area for a mean of 177 minutes (minimum-  
57 maximum: 59-210 minutes). 373 (88%) participants attended the 6 days Ag-RDT, all of them  
58 with negative results.  
59  
60

1  
2  
3 No positive SARS-CoV-2 cases were detected at 14 days in the exposition group, (estimated  
4 cumulative incidence (95% confidence interval): 0 (0, 943) / 100,000 inhabitants) and 2  
5 positive RT-PCR cases in the control group (cumulative incidence of 102 (12.4, 369) / 100,000  
6 inhabitants).  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



Table 2. Sample characteristics and outcomes in the sample of participants in the ‘Reobrim Sitges’ study, Overall and by role groups.

	n	Missings	Global	Organizers (n=18)	Security personnel (n=9)	Club workers (n=32)	Study Participants (n=332)	p-value
Age : Median [IQR]	391	0	37.00 [23.00, 50.00]	54.00 [48.25, 57.00]	41.00 [38.00, 46.00]	29.00 [25.00, 40.25]	35.50 [23.00, 50.00]	<0.001
Age : Mean (SD)			37.54 (15.53)	51.67 (8.60)	41.44 (6.95)	33.06 (10.53)	37.10 (15.99)	<0.001
Sex : n (%)	391	0						0.017
<i>Women</i>			173 (44.25%)	8 (44.44%)	0 (0.00%)	10 (31.25%)	155 (46.69%)	
<i>Men</i>			218 (55.75%)	10 (55.56%)	9 (100.00%)	22 (68.75%)	177 (53.31%)	
MEDEA Deprivation Index : Median [IQR]	374	17	-0.32 [-0.32, 0.48]	-0.32 [-0.32, -0.14]	0.64 [0.48, 1.07]	-0.32 [-0.32, 0.64]	-0.32 [-0.32, 0.48]	0.022
MEDEA Deprivation Index : Mean (SD)			0.04 (0.59)	-0.03 (0.64)	0.79 (0.49)	0.09 (0.67)	0.02 (0.58)	0.015
MEDEA Deprivation Index Categories: n (%)	391	0						<0.001
<i>Least deprived Septiles (28.6%)</i>			16 (4.09%)	0 (0.00%)	0 (0.00%)	1 (3.12%)	15 (4.52%)	
<i>Most deprived Septiles (28.6%)</i>			98 (25.06%)	3 (16.67%)	5 (55.56%)	9 (28.12%)	81 (24.40%)	
<i>3 Central Septiles (42.8%)</i>			260 (66.50%)	13 (72.22%)	1 (11.11%)	21 (65.62%)	225 (67.77%)	
<i>No Medea</i>			17 (4.35%)	2 (11.11%)	3 (33.33%)	1 (3.12%)	11 (3.31%)	
Previous infection : n (%)	391	0	35 (8.95%)	3 (16.67%)	0 (0.00%)	2 (6.25%)	30 (9.04%)	0.477
Previous infection date : Median (IQR)	35	356	2020-11-02 [2020-08-17, 2021-01-08]	2021-01-13 [2020-11-04, 2021-01-17]	-	2021-01-19 [2021-01-02, 2021-02-05]	2020-10-15 [2020-08-12, 2021-01-03]	0.256
First vaccination : n (%)	391	0	42 (10.74%)	1 (5.56%)	0 (0.00%)	2 (6.25%)	39 (11.75%)	0.456
Vaccine 1 company : n (%)	42	349						
<i>BioNTech / Pfizer</i>			17 (40.48%)	1 (100.00%)	-	0 (0.00%)	16 (41.03%)	
<i>Moderna</i>			8 (19.05%)	0 (0.00%)	-	2 (100.00%)	6 (15.38%)	
<i>Oxford / AstraZeneca</i>			17 (40.48%)	0 (0.00%)	-	0 (0.00%)	17 (43.59%)	
Second vaccination : n (%)	391	0	23 (5.88%)	1 (5.56%)	0 (0.00%)	2 (6.25%)	20 (6.02%)	0.900
Vaccine 2 company : n (%)	23	368						
<i>BioNTech / Pfizer</i>			15 (65.22%)	1 (100.00%)	-	0 (0.00%)	14 (70.00%)	
<i>Moderna</i>			7 (30.43%)	0 (0.00%)	-	2 (100.00%)	5 (25.00%)	
<i>Oxford / AstraZeneca</i>			1 (4.35%)	0 (0.00%)	-	0 (0.00%)	1 (5.00%)	
Vaccinated and infected : n (%)	391	0	73 (18.67%)	4 (22.22%)	0 (0.00%)	3 (9.38%)	66 (19.88%)	0.225
Follow-up Ag-RTD at 6 days : n (%)	391	0						0.069
<i>Negative result</i>			344 (87.98%)	17 (94.44%)	6 (66.67%)	31 (96.88%)	290 (87.35%)	
<i>Not attending</i>			47 (12.02%)	1 (5.56%)	3 (33.33%)	1 (3.12%)	42 (12.65%)	
Extra tests at 14 days	18	373						-
<i>PCR</i>			13 (72.22%)	-	2 (100.00%)	2 (100.00%)	9 (64.29%)	
<i>TAR</i>			5 (27.78%)	-	0 (0.00%)	0 (0.00%)	5 (35.71%)	
Test results at 14 days	18	373						-
<i>Negative result</i>			18 (100.00%)	-	2 (100.00%)	2 (100.00%)	14 (100.00%)	

## DISCUSSION

### Key results

The 'Reobrim Sitges' nightlife study loosening alarm state restrictions in small clubs resulted in no positive SARS-CoV-2 test results among participants at the 14 days follow-up, while in the control group 2 positive cases were detected without statistically significant differences. This study adds new evidence to the other studies assessing the impact of the reopening of the social and cultural nightlife.

### Comparison with previous studies

Up to date, most of articles studying COVID-19 in mass-gathering events either reported retrospective analyses of SARS-CoV-2 transmission [19–21] or described mitigation plans and measures applied during mass-gathering events [22,23]. Only one controlled trial was published in Catalonia [13].

Revollo et al. [13] present a randomized controlled trial assessing the impact, in terms of SARS-CoV-2 infections, of attending a live gig in a medium-sized concert hall (capacity of 900 people) in Barcelona, on December 2020. 1047 individuals aged 18-59 years with a negative Ag-RDT on the same day, no comorbidities, and declaring not having a positive COVID-19 diagnose during the last 14 days were randomly assigned to the experimental group and attended the indoor event (at 50% of hall's capacity; n=465), or sent home (control group, n=495). With a mean staying time of 2:40 hours, 8 days after the event no positive RT-PCR tests were found in the intervention group, whereas two (<1%) individuals in the control arm had a positive Ag-RDT and RT-PCR results. Common elements with our study are: sample size, use of Ag-RDT as inclusion criteria, age ranges, freedom of movement with no social distance, and use of masks (although both FFP2 and quirurgical were allowed in our study). Both studies obtained similar results, despite in ours a) drinking was allowed in the entire perimeter, and b) the event was developed in locals with indoor capacities below 100 people without indoor air quality control, and with bigger outdoor areas.

On March 2021, an observational study assessed the impact of attending to a live gig in a big concert hall in Barcelona: 4.584 attendees (below 30% of 17,000 persons hall's capacity) with negative Ag-RDT simultaneously enjoyed the experience in three isolated groups. No social distancing and wearing FFP2 masks were required, and independent drinking areas were habilitated. It resulted in a cumulative incidence at 14 days of 131infections per 100,000 inhabitants. This, compared to the age-adjusted estimation of 296/100,000 observed in the city of Barcelona for the same period, supposed no significant impact due to the event [14], in line with our results.

As aforementioned, the press has published other experiences such as the "Obrir Girona" initiative [15], performed from April 23rd to May 22nd 2021 in Girona, assessing the impact of reactivating a broader range of social activities under "very low infection capacity" conditions. Social activities included dinners in restaurants, an electronic music gig (250 attendees at full capacity, wearing masks -drinking allowed in independent room- with no social distance), and a pop gig (1,000 attendees at 56% capacity, wearing masks -drinking allowed at exterior bar- with no social distance). "Very low infection capacity" was considered if participants were

1  
2  
3 vaccinated in the last 6 months, had overcome COVID-19 in the last 3 months, or had a  
4 negative Ag-RDT in the last 36 hours. Of the 1,350, only 3 participants got a positive test  
5 between day 7 and 14 after the events [24]. Remarkably, the study inclusion criteria of  
6 participants relied on not only Ag-RDT screening, but also considered recent vaccination or  
7 infection as an indicator of low infection capacity. Despite its heterogeneity in social activities  
8 and locations, the observed low incidence rate supports their low infection capacity criterium.  
9

10  
11 Other projects have been developed in Netherlands and United Kingdom to examine how  
12 events can be reopened with reduced risk [25,26]. Fitzgerald et al [27] explored the  
13 management of COVID-19 restrictions to operate safely in licensed premises. Physical  
14 distancing, which was not required in the present study, was one of the more challenging. A  
15 pilot study in Liverpool explored the nightclubs reopening in semi-controlled settings [28].  
16 Despite differences in the methodology, results were in line with ours; an exploratory modelling  
17 of transmission risks at nightclubs suggests that primary transmissions are reduced by 53%  
18 through testing on the day.  
19

20  
21 Informally, if these unpublished results were right, social activities in Catalonia under sanitary  
22 controlled access would have resulted in 9 people infected at 14 days out of 6739 participants  
23 up to date. However, press information has attributed to the three extraordinarily authorized  
24 festivals in Catalonia on July 2021 a risk of infection around 1.7 times higher than expected  
25 [29,30]. Without a published official report, the inefficiency of the Ag-RDT control process in  
26 one of the events, and the relaxation in the use of masks after several hours in a considered  
27 safe environment, along with the apparition of more contagious SARS-CoV-2 variants, were  
28 pointed out as possible causes for such bad results in comparison to pilot studies. This led to  
29 new limitations and highlighted the importance of vaccination and the cumulative protective  
30 effect of Ag-RDT tests and masks in these scenarios.  
31

32  
33 Generalisability On July 29th, after few weeks of alarming negative evolution, especially in the  
34 15-24 age range population, the Catalan government decided to suppress the reopening of  
35 nightlife social activities [31]. The opening of such activities had been done until then without  
36 any sanitary access control, exclusively with mandated use of masks. The dissonance  
37 between results of controlled studies and real life, apart from the higher transmissibility of the  
38 delta variant, highlights the importance of this access control and sanitary measures when  
39 reducing the spreading of the virus.  
40

41  
42 Despite Ag-RDT lacks in high sensitivity [9] evidence supports its use, along with other  
43 measures, to ensure safe enough environments for mass-gathering (nightlife) events; a low-  
44 cost, easy performance and quick-result test seems a good option for a wide range of social  
45 activities. Nonetheless, the use of Ag-RDT test needs to be evaluated in every situation  
46 depending on the type of activity and the epidemiological data at the time of the event,  
47 including rate of vaccination [32]. Each real situation needs to balance the benefits of having  
48 rapid Ag-RDT results for immediate and appropriate management and public health action  
49 against the harm of false negative results [32]. In our study, as the two studies in Barcelona,  
50 the organization provided the tests the same day. This guarantees the temporal proximity to  
51 the event and the inalterability of results, but requires a logistic, sanitary and economic effort,  
52 which could be assumable for large events but hardly for small clubs' nightlife. Moreover,  
53 performing tests does not exclude the necessity to follow other security measures, as the use  
54 of the mask [26]. Applications in line with the "Re-open EU" or the one used in the "Obrir  
55  
56  
57  
58  
59  
60

1  
2  
3 Girona” study can be a useful tool for reporting low infection capacity probable from different  
4 sources.  
5

6  
7 The highly variable context/situation hinders the reproducibility of these types of studies. The  
8 extension of vaccination to all age ranges along with sanitary access control to nightlife  
9 activities should provide a safer nightlife environment, necessary to recover social and  
10 economic activities, while to discouraging uncontrolled nightlife “botellón” (street alcohol  
11 consumption) and illegal private massive events.  
12

13  
14 During our study, the first cases of SARS-CoV-2 Delta variant had been detected in Spain;  
15 this variant seems to be around 60% more transmissible than the Alpha variant. Thus, Delta  
16 variant is spreading worldwide as the fittest and fastest variant and it is becoming dominant in  
17 many countries. Evidence in the UK shows that 75% of infections by Delta variant are  
18 occurring in people who are not vaccinated and about 4 to 57% in people who are fully  
19 vaccinated [33], thus affecting age ranges more prone to enjoy nightlife. Moreover, incidence  
20 rates were in regression [12]. More research is needed to ensure our results can be  
21 extrapolated to the Delta and future variants, and in the different scenarios of transmissibility.  
22

### 23 24 Strengths and limitations

25  
26 Some limitations are present in our study. The selection of volunteers was non-random  
27 (convenience sampling), with the aim of including a profile of clients specific of each nightclub.  
28 To adjust for this selection bias, a control group matched by age, sex, and socioeconomic  
29 index, history of previous SARS CoV-2 infection, and SARS CoV-2 vaccine status was sought.  
30 However, a residual bias cannot be ruled out as a result of other parameters that we cannot  
31 control.  
32  
33

34  
35 On the other hand, both the volunteers and the control group evidence of infections at 14 days  
36 was obtained through EHR, and we may not have detected asymptomatic or mild symptomatic  
37 cases that were not consulted by health systems. This fact was minimized in the intervention  
38 group with the performance of the Ag-RDT follow-up test 6 days after the intervention, with an  
39 acceptable loss rate of 12% (as compared to similar studies in the UK earlier this year [28]).  
40 Despite the lower sensitivity and specificity of the Ag-RDT test, this follow-up increased the  
41 likelihood of measuring the impact of the intervention on the onset of new infections, at risk of  
42 overestimating the negative impact of the intervention. However, not presenting baseline tests  
43 could lead to another bias in the contrary direction; we expect that those crossed biases would  
44 minimize overall bias  
45  
46

### 47 48 Interpretation

49  
50 As a conclusion, in our study the attendance to nightclubs under controlled conditions and  
51 previous negative Ag-RDT did not show an increased transmissibility of SARS-CoV-2. These  
52 results, within the framework of health and safety, provide insight into the possibility of more  
53 secure apertures for event organizers.  
54  
55  
56  
57  
58  
59  
60

### ACKNOWLEDGMENTS

We would like to thank Carles Cortés, Eva Lacasta, David Alburquerque, Mercè Fernandez and the whole team of Ajuntament de Sitges (Sitges City Council) that made it possible, Damià Orts and the Associació d'Establiments d'Oci Nocturn de Sitges (Association of Nightlife Premises of Sitges) and Glòria Cabrera and the Federació Catalana de Locals d'Oci Nocturn (Catalan Federation of Nightclubs) for the counseling in the design of the study and dissemination, and Esther Sancho and the whole Curasana team.

### DECLARATION OF INTERESTS

The authors declare no conflict of interest.

### DATA AVAILABILITY STATEMENT

Due to ethical reasons stated by the Ethics Comitee, data can not be made available.

### FUNDING

The Sitges Council funded the initiative (covering all test, organization and security costs), relying on the Catalan Public Health Agency to develop it. Award/Grant number is not applicable.

They did not intervene in the analysis, discussion or publications of results.

### CONTRIBUTORS

OC: Study design, data analysis and manuscript elaboration. SC: Study design and manuscript elaboration. MM: Study design and manuscript elaboration. DL: Study design and manuscript elaboration. MA: Study design, data extraction and manuscript revision. JA: Study design and manuscript elaboration. JC: Conception, study design and manuscript revision. JB: Conception, study design and manuscript revision. BS: Conception, study design and manuscript elaboration. All authors have approved the final version of the manuscript.

## REFERENCES

- 1 Johns Hopkins University. Center for Systems Science and Engineering (CSSE). Coronavirus COVID-19 (2019-nCoV). <https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6> (accessed 13 Aug 2021).
- 2 Jayaweera M, Perera H, Gunawardana B, *et al.* Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. *Environ Res* 2020;**188**:109819. doi:10.1016/J.ENVRES.2020.109819
- 3 Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. *Ann Intern Med* 2020;**173**:362–7. doi:10.7326/M20-3012
- 4 Somsen GA, van Rijn C, Kooij S, *et al.* Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. *Lancet Respir Med* 2020;**8**:658. doi:10.1016/S2213-2600(20)30245-9
- 5 World Health Organization. Coronavirus disease (COVID-19). 2020.<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19> (accessed 13 Aug 2021).
- 6 Lauer S, Grantz K, Bi Q, *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med* 2020;**172**:577–82. doi:10.7326/M20-0504
- 7 Wang W, Xu Y, Gao R, *et al.* Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* 2020;**323**:1843. doi:10.1001/JAMA.2020.3786
- 8 Younes N, Al-Sadeq DW, Al-Jighefee H, *et al.* Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. *Viruses* 2020;**12**:582. doi:10.3390/v12060582
- 9 World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. 2020.<https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays> (accessed 13 Aug 2021).
- 10 Mina MJ, Peto TE, García-Fiñana M, *et al.* Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19. *Lancet* Published Online First: 17 February 2021. doi:10.1016/S0140-6736(21)00425-6
- 11 Ministerio de la Presidencia R con las C y MD. Real Decreto 463/2020, de 14 de marzo, por el que se declara el estado de alarma para la gestión de la situación de crisis sanitaria ocasionada por el COVID-19. 2020. <https://www.boe.es/buscar/pdf/2020/BOE-A-2020-3692-consolidado.pdf> (accessed 13 Aug 2021).
- 12 Departament de Salut. Generalitat de Catalunya. Dades COVID . 2021.<https://dadescovid.cat> (accessed 13 Aug 2021).
- 13 Revollo B, Blanco I, Soler P, *et al.* Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. *Lancet* Published Online First: 2021. doi:10.1016/S1473-3099(21)00268-1
- 14 Llibre JM, Videla S, Clotet B, *et al.* Screening for SARS-CoV-2 Antigen Before a Live Indoor Music Concert: An Observational Study. *Ann Intern Med* Published Online First: 20 July 2021. doi:10.7326/M21-2278
- 15 Centre Blockchain de Catalunya. Obrir Girona – CBCat. 2021.<https://obrirgirona.cat/> (accessed 13 Aug 2021).

- 1  
2  
3 16 Generalitat de Catalunya. Departament de Salut. Procediment d'actuació enfront de  
4 casos d'infecció pel nou coronavirus SARS-CoV-2 Sub-direcció General de Vigilància  
5 i Resposta a Emergències de Salut Pública. 2021.  
6 [https://canalsalut.gencat.cat/web/.content/\\_A-Z/C/coronavirus-2019-ncov/material-](https://canalsalut.gencat.cat/web/.content/_A-Z/C/coronavirus-2019-ncov/material-)  
7 (accessed 13 Aug 2021).  
8
- 9 17 Gobierno de España. Ministerio de Sanidad. Estrategia de detección precoz,  
10 vigilancia y control de COVID-19. 2021.  
11
- 12 18 Domínguez-Berjón MF, Borrell C, Cano-Serral G, *et al.* [Constructing a deprivation  
13 index based on census data in large Spanish cities (the MEDEA project)]. *Gac Sanit*  
14 2008;**22**:179–87. doi:10.1157/13123961  
15
- 16 19 Mat NFC, Edinur HA, Razab MKAA, *et al.* A Single Mass Gathering Resulted in  
17 Massive Transmission of COVID-19 Infections in Malaysia with Further International  
18 Spread. *J Travel Med* 2020;**27**. doi:10.1093/JTM/TAAA059  
19
- 20 20 Pavli A, Smeti P, Papadima K, *et al.* A cluster of COVID-19 in pilgrims to Israel. *J*  
21 *Travel Med* 2020;**27**:1–3. doi:10.1093/JTM/TAAA102  
22
- 23 21 Shmuel K, Dalia M, Tair L, *et al.* Low pH Hypromellose (Taffix) nasal powder spray  
24 could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly  
25 endemic community: an observational prospective open label user survey. *Expert Rev*  
26 *Anti Infect Ther* 2021; 1. doi:10.1080/14787210.2021.1908127  
27
- 28 22 Limbachia J, Owens H, Matean M, *et al.* Organizing a Mass Gathering Amidst a  
29 Rising COVID-19 Public Health Crisis: Lessons Learned From a Chinese Public  
30 Health Forum in Vancouver, BC. *Cureus* Published Online First: 29 December 2020.  
31 doi:10.7759/cureus.12365  
32
- 33 23 McCloskey B, Zumla A, Ippolito G, *et al.* Mass gathering events and reducing further  
34 global spread of COVID-19: a political and public health dilemma. *Lancet*  
35 2020;**395**:1096. doi:10.1016/S0140-6736(20)30681-4  
36
- 37 24 Agència Catalana de Notícies. Els impulsors d'Obrir Girona demanen ampliar el  
38 programa a tot Catalunya després de l'èxit de la prova - Diari de Girona.  
39 2021.[https://www.diaridegirona.cat/girona/2021/06/04/els-impulsors-dobrir-girona-](https://www.diaridegirona.cat/girona/2021/06/04/els-impulsors-dobrir-girona-demanen-52621652.html)  
40 [demanen-52621652.html](https://www.diaridegirona.cat/girona/2021/06/04/els-impulsors-dobrir-girona-demanen-52621652.html) (accessed 13 Aug 2021).  
41
- 42 25 Dutch government. Fieldlab Evenementen.  
43 2020.<https://fieldlabevenementen.nl/fieldlab-english/> (accessed 13 Aug 2021).  
44
- 45 26 Gov.UK. Information on the Events Research Programme - GOV.UK.  
46 2021.[https://www.gov.uk/government/publications/information-on-the-events-](https://www.gov.uk/government/publications/information-on-the-events-research-programme)  
47 [research-programme](https://www.gov.uk/government/publications/information-on-the-events-research-programme) (accessed 13 Aug 2021).  
48
- 49 27 Fitzgerald N, Uny I, Brown A, *et al.* Managing COVID-19 Transmission Risks in Bars:  
50 An Interview and Observation Study. *J Stud Alcohol Drugs*, 2021; **82**: 42-54. doi:  
51 10.15288/jsad.2021.82.42  
52
- 53 28 Department for Digital Culture Media and Sport - Gov.UK. Events Research  
54 Programme: Phase I findings - GOV.UK.  
55 2021.[https://www.gov.uk/government/publications/events-research-programme-](https://www.gov.uk/government/publications/events-research-programme-phase-i-findings/events-research-programme-phase-i-findings)  
56 [phase-i-findings/events-research-programme-phase-i-findings](https://www.gov.uk/government/publications/events-research-programme-phase-i-findings/events-research-programme-phase-i-findings) (accessed 13 Aug  
57 2021).  
58
- 59 29 Mouzo J. Los festivales de música en Cataluña aumentaron la transmisión de la  
60 covid: más de 2.000 asistentes se infectaron. El País.  
2021.[https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-](https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-infectaron.html)  
[cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-](https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-infectaron.html)  
[infectaron.html](https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-infectaron.html) (accessed 13 Aug 2021).

- 1  
2  
3 30 Cabezas C. Roda de premsa sobre el seguiment del procés de vacunació de la  
4 COVID-19 a Catalunya.  
5 2011;:31:55.<https://www.youtube.com/watch?v=9MUfakIxVSA&t=1915s> (accessed 13  
6 Aug 2021).  
7  
8 31 Diari Oficial de la Generalitat de Catalunya. RESOLUCIÓ SLT/2498/2021. Barcelona:  
9 Generalitat de Catalunya 2021. [https://dogc.gencat.cat/ca/document-del-](https://dogc.gencat.cat/ca/document-del-dogc/?documentId=907691)  
10 [dogc/?documentId=907691](https://dogc.gencat.cat/ca/document-del-dogc/?documentId=907691) (accessed 13 Aug 2021).  
11  
12 32 Peeling RW, Olliaro PL, Boeras DI, *et al.* Scaling up COVID-19 rapid antigen tests:  
13 promises and challenges. *Lancet Infect Dis* Published Online First: 2021.  
14 doi:10.1016/S1473-3099(21)00048-7  
15  
16 33 Public Health England. SARS-CoV-2 variants of concern and variants under  
17 investigation in England. Technical Briefing 15. 2021.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
<b>Title and abstract</b>			
Title	<a href="#">#1a</a>	Indicate the study's design with a commonly used term in the title or the abstract	3
Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background / rationale	<a href="#">#2</a>	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	<a href="#">#3</a>	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	<a href="#">#4</a>	Present key elements of study design early in the paper	5
Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant dates, including periods	5-6

1		of recruitment, exposure, follow-up, and data collection		
2	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.	5-6
3				
4				
5				
6	Eligibility criteria	<a href="#">#6b</a>	For matched studies, give matching criteria and number of exposed and unexposed	6
7				
8				
9				
10	Variables	<a href="#">#7</a>	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
11				
12				
13				
14				
15	Data sources /	<a href="#">#8</a>	For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. Give information separately for for exposed and unexposed groups if applicable.	6
16	measurement			
17				
18				
19				
20				
21				
22	Bias	<a href="#">#9</a>	Describe any efforts to address potential sources of bias	6
23				
24	Study size	<a href="#">#10</a>	Explain how the study size was arrived at	6
25				
26				
27	Quantitative	<a href="#">#11</a>	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	6
28	variables			
29				
30				
31	Statistical	<a href="#">#12a</a>	Describe all statistical methods, including those used to control for confounding	
32	methods			
33				
34	6			
35				
36				
37	Statistical	<a href="#">#12b</a>	Describe any methods used to examine subgroups and interactions	6
38	methods			
39				
40				
41	Statistical	<a href="#">#12c</a>	Explain how missing data were addressed	6
42	methods			
43				
44	Statistical	<a href="#">#12d</a>	If applicable, explain how loss to follow-up was addressed	NA
45	methods			
46				
47				
48	Statistical	<a href="#">#12e</a>	Describe any sensitivity analyses	
49	methods			
50				
51				
52	NA			
53				
54	<b>Results</b>			
55				
56				
57	Participants	<a href="#">#13a</a>	Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible,	7
58				
59				
60				

included in the study, completing follow-up, and analysed. Give information separately for for exposed and unexposed groups if applicable.

1			
2			
3			
4			
5	Participants	<a href="#">#13b</a>	Give reasons for non-participation at each stage 7
6			
7	Participants	<a href="#">#13c</a>	Consider use of a flow diagram
8			
9	NA		
10			
11			
12	Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg demographic, clinical, 7-8 social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.
13			
14			
15			
16			
17			
18			
19	Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing data for each variable of interest
20			
21			
22			
23	8		
24			
25	Descriptive data	<a href="#">#14c</a>	Summarise follow-up time (eg, average and total amount)
26			
27			
28	7		
29			
30	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable.
31			
32			
33			
34			
35	8		
36			
37			
38	Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 8
39			
40			
41			
42			
43			
44	Main results	<a href="#">#16b</a>	Report category boundaries when continuous variables were categorized NA
45			
46			
47			
48	Main results	<a href="#">#16c</a>	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
49			
50			
51			
52	7		
53			
54			
55	Other analyses	<a href="#">#17</a>	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses NA
56			
57			

## Discussion

1	Key results	<a href="#">#18</a>	Summarise key results with reference to study objectives	9
2				
3	Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into account sources of	11
4			potential bias or imprecision. Discuss both direction and magnitude of	
5			any potential bias.	
6				
7				
8	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation considering objectives,	11
9			limitations, multiplicity of analyses, results from similar studies, and	
10			other relevant evidence.	
11				
12				
13	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external validity) of the study results	10-11
14				
15				
16	<b>Other</b>			
17	<b>Information</b>			
18				
19				
20	Funding	<a href="#">#22</a>	Give the source of funding and the role of the funders for the present	12
21			study and, if applicable, for the original study on which the present	
22			article is based	
23				
24				

25 The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY.

26 This checklist was completed on 05. October 2021 using <https://www.goodreports.org/>, a tool made by the

27 [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

# BMJ Open

## Evaluating the controlled reopening of nightlife during the COVID-19 pandemic: a matched cohort study in Sitges, Spain, in May 2021 (Reobrim Sitges)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058595.R2
Article Type:	Original research
Date Submitted by the Author:	24-Mar-2022
Complete List of Authors:	Cunillera Puértolas, Oriol; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona Contreras-Martos, Sara; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona Marzo-Castillejo, Mercè; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona López Gallegos, Darío; Institut Català De La Salut, Servei d'Atenció Primària Alt Penedès-Garraf-Baix Llobregat Nord, Direcció d'Atenció Primària Costa de Ponent Acedo Anta, Mateo; Institut Català de la Salut, Secretaria Tècnica, Direcció d'Atenció Primària Costa de Ponent; Universitat de Barcelona Facultat de Medicina i Ciències de la Salut, Escola d'Infermeria Almeda Ortega, Jesús; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona Colom, Joan; Agència de Salut Pública de Catalunya, Sub-direcció General de Drogodependències Basora, Josep; IDIAP Jordi Gol, Institut Universitari d'Investigació en Atenció Primària Salvador-Gonzalez, Betlem; IDIAP Jordi Gol, Unitat de Suport a la Recerca Costa de Ponent; Universitat Autònoma de Barcelona
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Epidemiology, Infectious diseases, Public health
Keywords:	COVID-19, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Public health < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Evaluating the controlled reopening of nightlife during the COVID-19 pandemic: a matched**  
4 **cohort study in Sitges, Spain, in May 2021 (Reobrim Sitges)**  
5

6 Oriol Cunillera Puértolas<sup>1,2</sup>

7 Sara Contreras-Martos<sup>1,2,3</sup>

8 Mercè Marzo- Castillejo<sup>1,2,3</sup>

9 Darío López Gallegos<sup>4</sup>

10 Mateo Acedo Anta<sup>5,6</sup>

11 Jesús Almeda Ortega<sup>1,2,3</sup>

12 Joan Colom Farran<sup>7</sup>

13 Josep Basora i Gallisà<sup>8</sup>

14 Betlem Salvador-González<sup>1,3</sup>

15  
16  
17  
18  
19  
20  
21 1-Unitat de Suport a la Recerca Costa de Ponent, Fundació Institut Universitari per a la recerca a  
22 l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Cornellà de Llobregat, Spain

23  
24 2-Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain.

25  
26 3-Unitat de Suport a la Recerca, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la  
27 Salut, L'Hospitalet de Llobregat, Spain

28  
29 4-Servei d'Atenció Primària Alt Penedès-Garraf-Baix Llobregat Nord, Direcció d'Atenció Primària Costa  
30 de Ponent, Institut Català de la Salut, L'Hospitalet de Llobregat, Spain.

31  
32 5-Secretaria Tècnica, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la Salut, Cornellà  
33 de Llobregat, Spain.

34  
35 6-Escola d'Infermeria, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona,  
36 Spain

37  
38 7-Subdirecció General de Drogodependències. ASPCAT. Departament de Salut, Generalitat de  
39 Catalunya, Barcelona, Spain.

40  
41 8-Institut Universitari d'Investigació en Atenció Primària (IDIAP Jordi Gol), Barcelona, Spain.

42  
43  
44 \* *Corresponding author:* Betlem Salvador-González

45 C/ Bellaterra, 41, 1er pis 08940 Cornellà de Llobregat, Barcelona

46 bsalvador@ambitcp.catsalut.net

47  
48 Word count: 3375 words  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## ABSTRACT

**Objectives:** To assess the impact of the relaxing of State of Alarm restrictions on SARS-CoV-2 infections at 14 days among people attending reopened nightclub venues.

**Design:** Matched cohort study with a paired control group (1:5 ratio).

**Setting:** Five small nightclubs with indoor areas and outdoor terraces, in a nightlife restricted area in Sitges, Spain, on May 20, 2021. Wearing masks was mandatory, drinking was allowed, and social distance was not required.

**Participants:** Volunteers were selected through a convenience sampling. To attend the event, participants were required to be older than 17 years, with a negative Ag-RDT test on the same afternoon, without a positive RT-PCR or Ag-RDT test and/or symptoms associated with COVID-19 in the previous 7 days, to not having knowingly been in close contact with someone infected in the previous 10 days, and to not have knowingly had close contact with someone with a suspicion of COVID-19 in the previous 48 hours. A control group was paired by exact age, gender, residence municipality, socioeconomic index, previous SARS-CoV-2 confirmed infection and vaccination status, in a 1:5 ratio, from the primary care electronic health records.

**Primary outcome:** Evidence of infection at electronic health records by SARS-CoV-2 at 14 days follow-up.

**Results:** Among the 391 participants (median age 37 years; 44% [n=173] women), no positive SARS-CoV-2 cases were detected at 14 days, resulting in a cumulative incidence estimation of 0 (95% CI 0, 943) per 100,000 inhabitants. In the control group, two cases with RT-PCR test were identified, resulting in a cumulative incidence of 102.30 (12.4, 369) per 100,000 inhabitants.

**Conclusions:** Nightlife attendance under controlled conditions and with a requirement for a negative Ag-RDT was not associated with increased transmissibility of SARS-CoV-2 in a pandemic context of low infection rates. In such circumstances, secure opening of the nightlife sector was possible, under reduced capacity, controlled access by Ag-RDT and environments where compliance with sanitary measures are maintainable.

### Strengths and limitations of this study

- Reobrim Sitges was a matched cohort study with convenience sampling and with a paired control group.
- Participants underwent Ag-RDT tests on the afternoon of the same day prior to accessing the event.
- Evidence of infection by SARS-CoV-2 at 14 days was obtained from the electronic health records.
- Ag-RDT follow-up tests six days after the intervention minimised unregistered infections in the participants who attended the event, with only 12% loss to follow-up.
- The background context of low infection rates at the time of the study, and the timing of the study during a previous phase of the pandemic (before the emergence and dominance of new variants), limits the generalisability of these findings.

## INTRODUCTION

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic had infected 186 million people and caused over 4 million deaths worldwide by July 12, 2021, with wide variability between countries and regions [1]. SARS-CoV-2 transmission mostly occurs by direct contact or through droplets and aerosols from an infected person located within two meters range and with exposure times of over 15 minutes [2,3]. Indoor, poorly ventilated, and crowded spaces [4] where people gather are hotspots for transmission of virus [5].

The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, has an incubation period that varies from 2 to 14 days. Among the symptomatic people, 50% develop symptoms within 5.1 days and 75% within 11.5 days [6].

The gold standard diagnostic test for SARS-Cov-2 is the real-time reverse-transcription polymerase chain reaction (RT-PCR), which detects viral RNA, presenting good results in terms of reliability, sensitivity and specificity [7]. Although RT-PCR can detect positive cases from the beginning of the infection in symptomatic and asymptomatic people, the need for well-equipped labs with specialised professionals increases the total delivery times and costs [8]. In contrast, the lateral flow immunochromatographic rapid antigen diagnostic tests (Ag-RDT) for SARS-CoV-2 can detect viral proteins and provide results *in situ* within 30 minutes. Although its sensitivity is below WHO recommendations, Ag-RDTs still offer the possibility of quick, easy and inexpensive SARS-CoV-2 detection in individuals who have high viral loads and hence are at high risk of transmitting the infection to others [9], which is the relevant issue for most public health measures [10].

The health and social crisis subsequent to the COVID-19 pandemic have forced many governments to deploy new social policies and legal restrictions, mostly focused on reducing the spread of COVID-19. In Spain, restrictions to mobility and economic activity (with temporary closure of restaurants, hotels and nightlife activities) began with the first State of Alarm in March 2020 [11]. At the time of writing of the first draft of this paper, September 2021, some restrictions on capacity limitations and opening hours still prevail. The balance between health and economy is still under study in the more flexible stage at this time: bars, restaurants, pubs, discotheques, and concert venues were still on the tightrope, claiming for secure measures allowing them to flounder.

Herd-immunity, mainly through mass vaccination, is the key goal to restoring social and economic activities in this sector. In Catalonia, on May 5, 2021, 30.5% of the population had received at least one dose, and 13.6% had completed vaccination [12]. Due to age prioritisation, only 6.9% of 18-24 years old Catalanian people and 11% aged 25-49 had some vaccination, thus constituting age ranges where legal measures were still prominent on controlling virus transmission.

Some studies have been carried out in Catalonia to assess the impact of relaxing legal restrictions on various types of social activities, including indoor gigs and dining passes in restaurants; although just two articles have been published to date [13,14], press conferences have disseminated some results on three initiatives [15]. None of these studies detected any increased risk associated with the exposures.

The aim of the present study was to assess the impact of the relaxing of State of Alarm restrictions on SARS-CoV-2 infections at 14 days among people attending reopened nightclub venues.

## METHODS

Reobrim Sitges was a matched cohort study, performed in a nightlife-restricted area in Sitges (Barcelona, Spain) on May 20, 2021.

The volunteers attending the event were recruited by convenience sampling promoted mainly through social networks by participating entities (council, guild, venues) and registered through the official city council website. Inclusion and exclusion criteria for all exposure groups (formed by study volunteers and staff groups) are defined in table 1. Participants underwent their Ag-RDT tests in scheduled intervals the afternoon of the event day in Sitges. The Ag-RDT test was performed by trained health professionals following manufacturer's instructions (AllTest, Ref. ICOV-502, Japan). The manufacturer's reported sensitivity and specificity were 96.4% and 99.9%, respectively.

**Table 1. Inclusion and exclusion criteria for study participants (volunteers and staff groups) attending the nightlife mass-gathering event**

Inclusion criteria	Exclusion criteria
1. Aged over 17	1. Declaring to have had a positive RT-PCR or Ag-RDT test in the last seven days
2. Living in Sitges area and Barcelona	2. Presenting symptoms associated with COVID-19 in the last seven days (according to Catalan Health Department protocols [16,17]):
3. Having a personal card from the Catalan public healthcare system	a) <i>at least one of these: fever, persistent cough, shortness of breath, anosmia, ageusia</i>
4. A negative Ag-RDT test the same afternoon (provided by the organisation).	b) <i>at least two of the following: sore throat, a cold, fatigue, myalgia, headache, vomiting or diarrhoea stomach ache</i>
	3. Having had close contact with someone infected in the last 10 days
	4. Having had close contact with someone suspected to have COVID-19 in the last 48 hours.

The nightlife event took place from 23:00 on May 20 to 03:00 on May 21, in a restricted street section, including five nightclubs with indoor areas (capacity 42-98 people) and outdoor terraces (capacity 15-35 people), with controlled registered access exclusively for participants. Mask was mandatory (surgical or FFP2), except while drinking or smoking. Drinking was

1  
2  
3 allowed indoors and outdoors. Social distancing was not required. Hydroalcoholic gel and  
4 panels reminding about COVID-19 safety standards and their participation in the study were  
5 distributed throughout the entire area. No special ventilation measures were required. A follow-  
6 up Ag-RDT test on day six after the event was performed on participants.  
7

8  
9 The control group was obtained through secondary data from the primary care electronic  
10 health records (PC-EHR), by a pseudonymised paired extraction of individuals not attending  
11 the social event. Pairing was executed by exact age, gender, residence municipality,  
12 socioeconomic index, previous SARS-CoV-2 confirmed infection and vaccination status (at  
13 least one dose administered), in a 1:5 ratio.  
14

15  
16 Sample size was conditioned on capacity limitations established at 75% of the venue's usual  
17 limits (according to and authorised by the Health Department within the context of this study),  
18 resulting in 400 volunteers. Considering the 14 days cumulative incidence of COVID-19  
19 occurring in the health district (Gerència Territorial Metropolitana Sud) on April 29, 2021  
20 (210/100,000 inhabitants [12]), significant differences would be found observing a 14-day  
21 incidence in the intervention group of 1.38% (six positive cases), with a significance level of  
22 0.05 and power of 0.8.  
23

24  
25 A participant flowchart is shown in figure 1.  
26

## 27 **Variables**

28  
29 The main outcome was a confirmed case (PCR, Ag-RDT and serology) of SARS-CoV-2  
30 infection at 14 days follow-up. As a secondary outcome, the number of positive Ag-RDTs  
31 performed in-person at six days in the exposure group was considered. The main outcome for  
32 the exposure group was gathered from both the 6-day follow-up Ag-RDT and any registry in  
33 the PC-EHR at 14 days follow-up and for the control group only from PC-EHR.  
34

35  
36 All other variables were obtained from PC-EHR: age, gender, MEDEA socioeconomic  
37 deprivation index [18] (classifying individuals into septiles), previous SARS-CoV-2 confirmed  
38 infection and previous vaccination: first and second intake, date, and vaccine commercial  
39 brand (BioNTech - Pfizer / Moderna / Oxford AstraZenecae/Janssen-Johnson&Johnson).  
40

41  
42 This information was collected for all participants, which were classified according to their role  
43 as Organisers, Security personnel, Club workers, or Volunteers.  
44

## 45 **Statistical analysis**

46  
47 All variables were described and compared by participant role groups. Median, interquartile  
48 range, mean and standard deviation were calculated for continuous variables, and absolute  
49 and relative frequencies were described for categorical variables. Homogeneity in distribution  
50 across roles was tested using Kruskal-Wallis or Chi-square tests and complete case analysis.  
51 As pairing was performed by the exact characteristics, no description is provided for the  
52 controls (presenting the same values as study participants).  
53

54  
55 Cumulative incidence was calculated for study participants as the number of positive cases at  
56 14 days divided by the total of individuals exposed, transformed into cases per 100,000  
57 inhabitants, and with confidence intervals estimated by the exact method.  
58  
59  
60

## Patient and public involvement

The Associació d'Establiments d'Oci Nocturn de Sitges (Association of Nightlife Premises of Sitges) and the Federació Catalana de Locals d'Oci Nocturn (Catalan Federation of Nightclubs) proposed and promoted the initiative and developed the initial proposal together with The Sitges Council. The Catalan Public Health Agency was contacted to adapt it to a formal study design and develop it, with the aforementioned entities participating in the conception and dissemination. The results were returned immediately to the entities for their dissemination.

## Ethical considerations

This study was approved by the Research Ethics Committee of the Institute for Primary Health Care Research Jordi Gol i Gurina (IDIAPJGol) and the Technical Committee of the Catalonia Civil Protection Plan (PROCICAT). The study guarantees compliance with the new General Data Protection Regulation (GDPR) EU 2016/679, the guidelines of the Principles of the Declaration of Helsinki and the Belmont Report.

Participants were informed about the project and signed a statement of compliance and informed consent to participate and allowed the use of their pseudonymised data exclusively for this project. Informed consent was not required for participants in the control group as the information was pseudonymised.

The external entity 'Curasana' ([www.curasana.org](http://www.curasana.org)) was responsible for the logistics and for performing Ag-RDT tests. The results were sent to the Catalan Institute of Health (ICS); positive results were communicated and entered into EHR for assistance purposes. The ICS and the IDIAPJGol were independently responsible for the data processing within the framework of this study.

## RESULTS

No positive Ag-RDTs tests were detected at baseline. The final exposure group included 391 participants (332 volunteers, 9 security staff, 32 bartenders/DJs, 18 organisers) who accessed the restricted nightlife area. Participants had a median/mean age of 37/37.5 years, 50% were between 23 and 50 years (Table 2). 55.8% (n=218) were male, and there was an under-representation of extreme Catalan socioeconomic ranges (especially the least deprived, with a 4.1% in front of the 28.6% in general population). About 9.0% (n=35) had previously been infected by SARS-CoV-2, 10.7% (n=42) had at least one vaccination dose and 19.7% (n=73) had been vaccinated as well as infected.

Staff groups were significantly different from volunteers in terms of age (organisers were significantly older), gender (due to a 100% male security personnel) and socioeconomic status (55.5% -5- of security personnel came from most deprived areas). Although not significant, security personnel and bartenders/DJs had lower vaccination and previous infection percentages. As the control group was matched by exact characteristics, it presented exactly the same distribution for all variables except for the outcomes.

Volunteers stayed in the restricted nightlife venue area for a mean of 177 minutes (minimum-maximum: 59-210 minutes). 373 (88%) participants attended the 6-day Ag-RDT, all of them with negative results.

1  
2  
3 No positive SARS-CoV-2 cases were detected at 14 days in the exposure group, (estimated  
4 cumulative incidence (95% confidence interval): 0 (0, 943) / 100,000 inhabitants) and 2  
5 positive RT-PCR cases in the control group (cumulative incidence of 102 (12.4, 369) / 100,000  
6 inhabitants).  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 2. Sample characteristics and outcomes, overall and by subgroup

	n	Missing	Global	Organisers (n=18)	Security personnel (n=9)	Club workers (n=32)	Study Participants (n=332)	p-value
Age: Median [IQR]	391	0	37.00 [23.00, 50.00]	54.00 [48.25, 57.00]	41.00 [38.00, 46.00]	29.00 [25.00, 40.25]	35.50 [23.00, 50.00]	<0.001
Age: Mean (SD)			37.54 (15.53)	51.67 (8.60)	41.44 (6.95)	33.06 (10.53)	37.10 (15.99)	<0.001
Gender: n (%)	391	0						0.017
<i>Women</i>			173 (44.25%)	8 (44.44%)	0 (0.00%)	10 (31.25%)	155 (46.69%)	
<i>Men</i>			218 (55.75%)	10 (55.56%)	9 (100.00%)	22 (68.75%)	177 (53.31%)	
MEDEA Deprivation Index: Median [IQR]	374	17	-0.32 [-0.32, 0.48]	-0.32 [-0.32, -0.14]	0.64 [0.48, 1.07]	-0.32 [-0.32, 0.64]	-0.32 [-0.32, 0.48]	0.022
MEDEA Deprivation Index: Mean (SD)			0.04 (0.59)	-0.03 (0.64)	0.79 (0.49)	0.09 (0.67)	0.02 (0.58)	0.015
MEDEA Deprivation Index Categories: n (%)	391	0						<0.001
<i>Least deprived Septiles (28.6%)</i>			16 (4.09%)	0 (0.00%)	0 (0.00%)	1 (3.12%)	15 (4.52%)	
<i>Most deprived Septiles (28.6%)</i>			98 (25.06%)	3 (16.67%)	5 (55.56%)	9 (28.12%)	81 (24.40%)	
<i>3 Central Septiles (42.8%)</i>			260 (66.50%)	13 (72.22%)	1 (11.11%)	21 (65.62%)	225 (67.77%)	
<i>No Medea</i>			17 (4.35%)	2 (11.11%)	3 (33.33%)	1 (3.12%)	11 (3.31%)	
Previous infection: n (%)	391	0	35 (8.95%)	3 (16.67%)	0 (0.00%)	2 (6.25%)	30 (9.04%)	0.477
Previous infection date: Median (IQR)	35	356	2020-11-02 [2020-08-17, 2021-01-08]	2021-01-13 [2020-11-04, 2021-01-17]	-	2021-01-19 [2021-01-02, 2021-02-05]	2020-10-15 [2020-08-12, 2021-01-03]	0.256
First vaccination: n (%)	391	0	42 (10.74%)	1 (5.56%)	0 (0.00%)	2 (6.25%)	39 (11.75%)	0.456
Vaccine 1 company: n (%)	42	349						
<i>BioNTech / Pfizer</i>			17 (40.48%)	1 (100.00%)	-	0 (0.00%)	16 (41.03%)	
<i>Moderna</i>			8 (19.05%)	0 (0.00%)	-	2 (100.00%)	6 (15.38%)	
<i>Oxford / AstraZeneca</i>			17 (40.48%)	0 (0.00%)	-	0 (0.00%)	17 (43.59%)	
Second vaccination: n (%)	391	0	23 (5.88%)	1 (5.56%)	0 (0.00%)	2 (6.25%)	20 (6.02%)	0.900
Vaccine 2 company: n (%)	23	368						
<i>BioNTech / Pfizer</i>			15 (65.22%)	1 (100.00%)	-	0 (0.00%)	14 (70.00%)	
<i>Moderna</i>			7 (30.43%)	0 (0.00%)	-	2 (100.00%)	5 (25.00%)	
<i>Oxford / AstraZeneca</i>			1 (4.35%)	0 (0.00%)	-	0 (0.00%)	1 (5.00%)	
Vaccinated and infected: n (%)	391	0	73 (18.67%)	4 (22.22%)	0 (0.00%)	3 (9.38%)	66 (19.88%)	0.225
Follow-up Ag-RDT at 6 days: n (%)	391	0						0.069
<i>Negative result</i>			344 (87.98%)	17 (94.44%)	6 (66.67%)	31 (96.88%)	290 (87.35%)	
<i>Not attending</i>			47 (12.02%)	1 (5.56%)	3 (33.33%)	1 (3.12%)	42 (12.65%)	
Extra tests at 14 days: n (%)	18	373						-
<i>PCR</i>			13 (72.22%)	-	2 (100.00%)	2 (100.00%)	9 (64.29%)	
<i>TAR</i>			5 (27.78%)	-	0 (0.00%)	0 (0.00%)	5 (35.71%)	
Test results at 14 days: n (%)	18	373						-
<i>Negative result</i>			18 (100.00%)	-	2 (100.00%)	2 (100.00%)	14 (100.00%)	

## DISCUSSION

### Key results

The Reobrim Sitges nightlife study loosening State of Alarm restrictions in small clubs resulted in no positive SARS-CoV-2 test results among participants at the 14 day follow-up, while two positive cases were detected in the control group without statistically significant differences. This study adds new evidence to other studies assessing the impact of reopening the social and cultural nightlife.

### Comparison with previous studies

To date, most articles studying COVID-19 in mass-gathering events either reported retrospective analyses of SARS-CoV-2 transmission [19–21] or described mitigation plans and measures applied during mass-gathering events [22,23]. Only one controlled trial was published in Catalonia [13].

Revollo et al. [13] present a randomised controlled trial assessing the impact, in terms of SARS-CoV-2 infections, of attending a live gig in a medium-size concert hall (capacity for 900 people) in Barcelona, in December 2020. 1047 individuals aged 18-59 years with a negative Ag-RDT on the same day, no comorbidities and declaring not to have had a positive COVID-19 diagnosis during the last 14 days were randomly assigned to the experimental group and attended the indoor event (at 50% of venue's capacity; n=465), or sent home (control group, n=495). With a mean staying time of 2:40 hours, eight days after the event no positive RT-PCR tests were found in the intervention group, whereas two (<1%) individuals in the control arm had a positive Ag-RDT and RT-PCR results. Common elements in this study are: sample size, use of Ag-RDT as inclusion criteria, age ranges, freedom of movement with no social distance and use of masks (although FFP2 and surgical masks were allowed in this study). Both studies obtained similar results, although in this study, a) drinking was allowed in the entire perimeter and b) the event was held in venues with indoor capacities below 100 people without indoor air quality control and with larger outdoor areas.

In March 2021, an observational study assessed the impact of attending a live gig in a large concert hall in Barcelona: 4,584 attendees (below 30% of the hall's 17,000-person capacity) with negative Ag-RDT simultaneously enjoyed the experience in three isolated groups. No social distancing, wearing FFP2 masks was required and independent drinking areas were established. The result was a cumulative incidence at 14 days of 131 infections per 100,000 inhabitants. This, compared to the age-adjusted estimation of 296/100,000 observed in the city of Barcelona for the same period, had no significant impact due to the event [14], in line with our results.

As mentioned previously, the press has published other experiences such as the "Obrir Girona" initiative [15], from April 23 to May 22, 2021 in Girona, assessing the impact of reactivating a broader range of social activities under "very low infection capacity" conditions. Social activities included dinners in restaurants, an electronic music gig (250 attendees at full capacity, wearing masks –drinking allowed in independent room– with no social distancing), and a pop gig (1,000 attendees at 56% capacity, wearing masks –drinking allowed at outdoor bar– with no social distancing). "Very low infection capacity" was considered if participants



1  
2  
3 were vaccinated in the last six months, had overcome COVID-19 in the last three months, or  
4 had a negative Ag-RDT in the last 36 hours. Of the 1,350 3 participants, only three had a  
5 positive test between day 7 and 14 after the events [24]. Remarkably, the study inclusion  
6 criteria for participants relied on Ag-RDT screening and also considered recent vaccination or  
7 infection as an indicator of low infection capacity. Despite its heterogeneity in social activities  
8 and locations, the observed low incidence rate supports their low infection capacity criterion.  
9  
10

11 Other projects have been undertaken in the Netherlands and United Kingdom to examine how  
12 events can be reopened with reduced risk [25,26]. Fitzgerald et al [27] explored the  
13 management of COVID-19 restrictions to operate safely in licensed premises. Physical  
14 distancing, which was not required in this study, was one of the more challenging aspects. A  
15 pilot study in Liverpool explored nightclubs reopening in semi-controlled settings [28]. Despite  
16 differences in the methodology, the results were in line with ours; an exploratory modelling of  
17 transmission risk at nightclubs suggests that primary transmissions are reduced by 53%  
18 through testing on the day.  
19  
20  
21

22 Informally, if these unpublished results were correct, social activities in Catalonia under  
23 sanitary controlled access would have resulted in 9 people infected at 14 days out of 6,739  
24 participants to date. However, press information has attributed to the three extraordinarily  
25 authorised festivals in Catalonia in July 2021, with an infection risk around 1.7 times higher  
26 than expected [29,30]. Without an official published report, the inefficiency of the Ag-RDT  
27 control process in one of the events, and the relaxation in the use of masks after several hours  
28 in an environment considered to be safe, along with the appearance of more contagious  
29 SARS-CoV-2 variants, were pointed out as possible causes for such poor results in  
30 comparison to pilot studies. This led to new limitations and highlighted the importance of  
31 vaccination and the cumulative protective effect of Ag-RDT tests and masks in these  
32 scenarios.  
33  
34  
35

### 36 Generalisability

37

38 On July 29, after a few weeks of reporting a negative evolution, especially in the 15-24 age  
39 range population, the Catalan government decided to suppress the reopening of nightlife  
40 social activities [31]. Such activities had been opened until then without any sanitary access  
41 control, exclusively with mandated use of masks. The dissonance between the results of  
42 controlled studies and real life, apart from the higher transmissibility of the delta variant,  
43 highlights the importance of access control and sanitary measures when reducing the spread  
44 of the virus.  
45  
46  
47

48 Despite Ag-RDT lacking high sensitivity [9] evidence supports its use, along with other  
49 measures, to ensure safe enough environments for mass-gathering (nightlife) events; a low-  
50 cost, easy performance and quick-result test seems a good option for a wide range of social  
51 activities. Nonetheless, the use of Ag-RDT test needs to be evaluated in every situation  
52 depending on the type of activity and the epidemiological data at the time of the event,  
53 including vaccination rate [32]. Each real situation needs to balance the benefits of having  
54 rapid Ag-RDT results for immediate and appropriate management and public health action  
55 against the harm of false negative results [32]. In this study, as in the two studies in Barcelona,  
56 the organisation provided the tests the same day. This guarantees the temporal proximity to  
57 the event and the inalterability of results, although logistic, sanitary and economic resources  
58  
59  
60

1  
2  
3 are required, which could be feasible for large events but not so much for nightlife in small  
4 clubs. Additionally, performing tests does not exclude the necessity to follow other safety  
5 measures, such as mask use [26]. Applications in line with the "Re-open EU" or the one used  
6 in the "Obrir Girona" study can be a useful tool for reporting low infection capacity probability  
7 from different sources.  
8  
9

10 The highly variable context/situation hinders the reproducibility of these types of studies. The  
11 extension of vaccination to all age ranges along with sanitary access control to nightlife  
12 activities should provide a safer nightlife environment, necessary to recover social and  
13 economic activities, while dis-encouraging uncontrolled nightlife "botellón" (street alcohol  
14 consumption) and illegal private mass events.  
15  
16

17 This study was performed when the first cases of SARS-CoV-2 Delta variant had been  
18 detected in Spain, the Delta variant being around 60% more transmissible than the  
19 predominant Alpha variant. Although the transmissibility context was determinant to allow  
20 ethical approval, the results presented must be carefully interpreted according to the low  
21 background infection rate at the time of the study. At that time, the pandemic was in a  
22 regression phase, with a cumulative incidence in Catalonia at 14 days of 210 cases per  
23 100,000 inhabitants [12]. Further research is therefore needed to ensure the results can be  
24 extrapolated to the Delta and future variants and in the different severity and transmissibility  
25 scenarios. Delta variant spread worldwide as the fittest and fastest variant until then and it  
26 became dominant in many countries. Evidence in the UK showed that 75% of infections by  
27 Delta variant occurred in people who were not vaccinated and about 4 to 57% in people who  
28 were fully vaccinated [33], thus affecting age ranges more disposed to enjoying nightlife.  
29  
30  
31

### 32 Strengths and limitations

33  
34  
35 There are limitations in this study. The selection of volunteers was non-random (convenience  
36 sampling), with the aim of including a profile of clients specific to each nightclub. To adjust for  
37 this selection bias, a control group matched by age, gender, and socioeconomic index, history  
38 of previous SARS CoV-2 infection and SARS CoV-2 vaccine status was sought. However, a  
39 residual bias cannot be ruled out as a result of other parameters that cannot control be  
40 controlled.  
41  
42

43 Many limitations are inherent to how SARS CoV-2 infection is measured, given the different  
44 criteria applied for intervention and control groups. At baseline, the intervention group received  
45 an Ag-RDT evaluation that was not applied in the control group, which was selected according  
46 to EHR without any additional prior check-up. Although sensitivity and specificity of the Ag-  
47 RDT tests are far from perfect, there is a higher probability of underestimating the presence  
48 of SARS-CoV-2 infection in the control group (i.e. having included asymptomatic or mild  
49 symptomatic cases not attended by health systems in the control group), which could reflect  
50 on a worse evolution of controls. Also, evidence of infections at 14 days was obtained for the  
51 volunteers and the control group through EHR, although the intervention group performed an  
52 Ag-RDT follow-up test six days after the intervention (with an acceptable loss rate of 12%, as  
53 compared to similar studies in the UK earlier this year [28]), which complemented EHR  
54 information. These follow-up tests increased the likelihood of measuring the impact of the  
55 intervention on the onset of new infections, reducing the underestimation of asymptomatic  
56 cases identified through EHR at follow-up only in the intervention group.  
57  
58  
59  
60

1  
2  
3 The highly fluctuating characteristics in transmissibility and severity of the different variants  
4 and phases during the pandemic hinder extrapolation of all studies' findings to the context in  
5 which they were developed. Therefore, aspects mentioned in the Generalisability section of  
6 the discussion are a major limitation for this study.  
7

### 8 9 Conclusion

10  
11 In conclusion, in this study, attendance to nightclubs under controlled conditions and with a  
12 requirement for negative Ag-RDT did not show an increased transmissibility of SARS-CoV-2  
13 in a pandemic context of low infection rates. These results, within the framework of health and  
14 safety, provide insight into the possibility of safer openings for event organizers.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ACKNOWLEDGMENTS

We would like to thank Carles Cortés, Eva Lacasta, David Alburquerque, Mercè Fernandez and the whole team of Ajuntament de Sitges (Sitges City Council) who made it possible, Damià Orts and the Associació d'Establiments d'Oci Nocturn de Sitges (Association of Nightlife Premises of Sitges) and Glòria Cabrera and the Federació Catalana de Locals d'Oci Nocturn (Catalan Federation of Nightclubs) for the advice on designing of the study and dissemination, and Esther Sancho and the whole Curasana team.

## CONTRIBUTORS

OC: Study design, data analysis and manuscript drafting. SC: Study design and manuscript draft. MM: Study design and manuscript draft. DL: Study design and manuscript draft. MA: Study design, data extraction and manuscript revision. JA: Study design and manuscript draft. JC: Conception, study design and manuscript revision. JB: Conception, study design and manuscript revision. BS: Conception, study design and manuscript drafting. All authors have approved the final version of the manuscript.

## COMPETING INTERESTS

The authors declare no conflicts of interest.

## FUNDING

The Sitges Council funded the initiative (covering all test, organisation and security costs), relying on the Catalan Public Health Agency for its development (award/grant number not applicable). The funder was not involved in the analysis, discussion or publication of results.

## DATA AVAILABILITY STATEMENT

Due to ethical reasons determined by the ethics committee, data can not be made available.

## REFERENCES


- 1 Johns Hopkins University. Center for Systems Science and Engineering (CSSE). Coronavirus COVID-19 (2019-nCoV). <https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6> (accessed 13 Aug 2021).
- 2 Jayaweera M, Perera H, Gunawardana B, *et al.* Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. *Environ Res* 2020;**188**:109819. doi:10.1016/J.ENVRES.2020.109819
- 3 Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. *Ann Intern Med* 2020;**173**:362–7. doi:10.7326/M20-3012
- 4 Somsen GA, van Rijn C, Kooij S, *et al.* Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. *Lancet Respir Med* 2020;**8**:658. doi:10.1016/S2213-2600(20)30245-9
- 5 World Health Organization. Coronavirus disease (COVID-19). 2020.<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19> (accessed 13 Aug 2021).
- 6 Lauer S, Grantz K, Bi Q, *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med* 2020;**172**:577–82. doi:10.7326/M20-0504
- 7 Wang W, Xu Y, Gao R, *et al.* Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* 2020;**323**:1843. doi:10.1001/JAMA.2020.3786
- 8 Younes N, Al-Sadeq DW, Al-Jighefee H, *et al.* Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. *Viruses* 2020;**12**:582. doi:10.3390/v12060582
- 9 World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. 2020.<https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays> (accessed 13 Aug 2021).
- 10 Mina MJ, Peto TE, García-Fiñana M, *et al.* Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19. *Lancet* Published Online First: 17 February 2021. doi:10.1016/S0140-6736(21)00425-6
- 11 Ministerio de la Presidencia R con las C y MD. Real Decreto 463/2020, de 14 de marzo, por el que se declara el estado de alarma para la gestión de la situación de crisis sanitaria ocasionada por el COVID-19. 2020. <https://www.boe.es/buscar/pdf/2020/BOE-A-2020-3692-consolidado.pdf> (accessed 13 Aug 2021).
- 12 Departament de Salut. Generalitat de Catalunya. Dades COVID . 2021.<https://dadescovid.cat> (accessed 13 Aug 2021).
- 13 Revollo B, Blanco I, Soler P, *et al.* Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. *Lancet* Published Online First: 2021. doi:10.1016/S1473-3099(21)00268-1
- 14 Llibre JM, Videla S, Clotet B, *et al.* Screening for SARS-CoV-2 Antigen Before a Live Indoor Music Concert: An Observational Study. *Ann Intern Med* Published Online First: 20 July 2021. doi:10.7326/M21-2278
- 15 Centre Blockchain de Catalunya. Obrir Girona – CBCat. 2021.<https://obrirgirona.cat/> (accessed 13 Aug 2021).

- 1  
2  
3 16 Generalitat de Catalunya. Departament de Salut. Procediment d'actuació enfront de  
4 casos d'infecció pel nou coronavirus SARS-CoV-2 Sub-direcció General de Vigilància  
5 i Resposta a Emergències de Salut Pública. 2021.  
6 [https://canalsalut.gencat.cat/web/.content/\\_A-Z/C/coronavirus-2019-ncov/material-](https://canalsalut.gencat.cat/web/.content/_A-Z/C/coronavirus-2019-ncov/material-)  
7 (accessed 13 Aug 2021).  
8
- 9 17 Gobierno de España. Ministerio de Sanidad. Estrategia de detección precoz,  
10 vigilancia y control de COVID-19. 2021.  
11
- 12 18 Domínguez-Berjón MF, Borrell C, Cano-Serral G, *et al.* [Constructing a deprivation  
13 index based on census data in large Spanish cities (the MEDEA project)]. *Gac Sanit*  
14 2008;**22**:179–87. doi:10.1157/13123961  
15
- 16 19 Mat NFC, Edinur HA, Razab MKAA, *et al.* A Single Mass Gathering Resulted in  
17 Massive Transmission of COVID-19 Infections in Malaysia with Further International  
18 Spread. *J Travel Med* 2020;**27**. doi:10.1093/JTM/TAAA059  
19
- 20 20 Pavli A, Smeti P, Papadima K, *et al.* A cluster of COVID-19 in pilgrims to Israel. *J*  
21 *Travel Med* 2020;**27**:1–3. doi:10.1093/JTM/TAAA102  
22
- 23 21 Shmuel K, Dalia M, Tair L, *et al.* Low pH Hypromellose (Taffix) nasal powder spray  
24 could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly  
25 endemic community: an observational prospective open label user survey. *Expert Rev*  
26 *Anti Infect Ther* 2021; 1. doi:10.1080/14787210.2021.1908127  
27
- 28 22 Limbachia J, Owens H, Matean M, *et al.* Organizing a Mass Gathering Amidst a  
29 Rising COVID-19 Public Health Crisis: Lessons Learned From a Chinese Public  
30 Health Forum in Vancouver, BC. *Cureus* Published Online First: 29 December 2020.  
31 doi:10.7759/cureus.12365  
32
- 33 23 McCloskey B, Zumla A, Ippolito G, *et al.* Mass gathering events and reducing further  
34 global spread of COVID-19: a political and public health dilemma. *Lancet*  
35 2020;**395**:1096. doi:10.1016/S0140-6736(20)30681-4  
36
- 37 24 Agència Catalana de Notícies. Els impulsors d'Obrir Girona demanen ampliar el  
38 programa a tot Catalunya després de l'èxit de la prova - Diari de Girona.  
39 2021.[https://www.diaridegirona.cat/girona/2021/06/04/els-impulsors-dobrir-girona-](https://www.diaridegirona.cat/girona/2021/06/04/els-impulsors-dobrir-girona-demanen-52621652.html)  
40 [demanen-52621652.html](https://www.diaridegirona.cat/girona/2021/06/04/els-impulsors-dobrir-girona-demanen-52621652.html) (accessed 13 Aug 2021).  
41
- 42 25 Dutch government. Fieldlab Evenementen.  
43 2020.<https://fieldlabevenementen.nl/fieldlab-english/> (accessed 13 Aug 2021).  
44
- 45 26 Gov.UK. Information on the Events Research Programme - GOV.UK.  
46 2021.[https://www.gov.uk/government/publications/information-on-the-events-](https://www.gov.uk/government/publications/information-on-the-events-research-programme)  
47 [research-programme](https://www.gov.uk/government/publications/information-on-the-events-research-programme) (accessed 13 Aug 2021).  
48
- 49 27 Fitzgerald N, Uny I, Brown A, *et al.* Managing COVID-19 Transmission Risks in Bars:  
50 An Interview and Observation Study. *J Stud Alcohol Drugs*, 2021; **82**: 42-54. doi:  
51 10.15288/jsad.2021.82.42  
52
- 53 28 Department for Digital Culture Media and Sport - Gov.UK. Events Research  
54 Programme: Phase I findings - GOV.UK.  
55 2021.[https://www.gov.uk/government/publications/events-research-programme-](https://www.gov.uk/government/publications/events-research-programme-phase-i-findings/events-research-programme-phase-i-findings)  
56 [phase-i-findings/events-research-programme-phase-i-findings](https://www.gov.uk/government/publications/events-research-programme-phase-i-findings/events-research-programme-phase-i-findings) (accessed 13 Aug  
57 2021).  
58
- 59 29 Mouzo J. Los festivales de música en Cataluña aumentaron la transmisión de la  
60 covid: más de 2.000 asistentes se infectaron. El País.  
2021.[https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-](https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-infectaron.html)  
[cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-](https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-infectaron.html)  
[infectaron.html](https://elpais.com/espana/catalunya/2021-08-04/los-festivales-de-musica-en-cataluna-aumentaron-la-transmision-de-la-covid-mas-de-2000-asistentes-se-infectaron.html) (accessed 13 Aug 2021).

- 1  
2  
3 30 Cabezas C. Roda de premsa sobre el seguiment del procés de vacunació de la  
4 COVID-19 a Catalunya.  
5 2011;:31:55.<https://www.youtube.com/watch?v=9MUfakIxVSA&t=1915s> (accessed 13  
6 Aug 2021).  
7  
8 31 Diari Oficial de la Generalitat de Catalunya. RESOLUCIÓ SLT/2498/2021. Barcelona:  
9 Generalitat de Catalunya 2021. [https://dogc.gencat.cat/ca/document-del-](https://dogc.gencat.cat/ca/document-del-dogc/?documentId=907691)  
10 [dogc/?documentId=907691](https://dogc.gencat.cat/ca/document-del-dogc/?documentId=907691) (accessed 13 Aug 2021).  
11  
12 32 Peeling RW, Olliaro PL, Boeras DI, *et al.* Scaling up COVID-19 rapid antigen tests:  
13 promises and challenges. *Lancet Infect Dis* Published Online First: 2021.  
14 doi:10.1016/S1473-3099(21)00048-7  
15  
16 33 Public Health England. SARS-CoV-2 variants of concern and variants under  
17 investigation in England. Technical Briefing 15. 2021.  
18  
19  
20

21 **Figure 1: Participant flowchart**  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





# Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
<b>Title and abstract</b>			
Title	<a href="#">#1a</a>	Indicate the study's design with a commonly used term in the title or the abstract	3
Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background / rationale	<a href="#">#2</a>	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	<a href="#">#3</a>	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	<a href="#">#4</a>	Present key elements of study design early in the paper	5
Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant dates, including periods	5-6

		of recruitment, exposure, follow-up, and data collection	
1			
2	Eligibility criteria	<a href="#">#6a</a> Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.	5-6
3			
4			
5			
6	Eligibility criteria	<a href="#">#6b</a> For matched studies, give matching criteria and number of exposed and unexposed	6
7			
8			
9			
10	Variables	<a href="#">#7</a> Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
11			
12			
13			
14			
15	Data sources / measurement	<a href="#">#8</a> For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. Give information separately for for exposed and unexposed groups if applicable.	6
16			
17			
18			
19			
20			
21			
22	Bias	<a href="#">#9</a> Describe any efforts to address potential sources of bias	6
23			
24	Study size	<a href="#">#10</a> Explain how the study size was arrived at	6
25			
26			
27	Quantitative variables	<a href="#">#11</a> Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	6
28			
29			
30			
31	Statistical methods	<a href="#">#12a</a> Describe all statistical methods, including those used to control for confounding	
32			
33			
34	6		
35			
36			
37	Statistical methods	<a href="#">#12b</a> Describe any methods used to examine subgroups and interactions	6
38			
39			
40			
41	Statistical methods	<a href="#">#12c</a> Explain how missing data were addressed	6
42			
43			
44	Statistical methods	<a href="#">#12d</a> If applicable, explain how loss to follow-up was addressed	NA
45			
46			
47			
48	Statistical methods	<a href="#">#12e</a> Describe any sensitivity analyses	
49			
50			
51			
52	NA		
53			
54	<b>Results</b>		
55			
56			
57	Participants	<a href="#">#13a</a> Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible,	7
58			
59			
60			

included in the study, completing follow-up, and analysed. Give information separately for for exposed and unexposed groups if applicable.

1			
2			
3			
4			
5	Participants	<a href="#">#13b</a>	Give reasons for non-participation at each stage 7
6			
7	Participants	<a href="#">#13c</a>	Consider use of a flow diagram
8			
9			
10	NA		
11			
12	Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg demographic, clinical, 7-8 social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.
13			
14			
15			
16			
17			
18			
19	Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing data for each variable of interest
20			
21			
22			
23	8		
24			
25	Descriptive data	<a href="#">#14c</a>	Summarise follow-up time (eg, average and total amount)
26			
27			
28	7		
29			
30	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable.
31			
32			
33			
34			
35	8		
36			
37			
38	Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 8
39			
40			
41			
42			
43			
44	Main results	<a href="#">#16b</a>	Report category boundaries when continuous variables were categorized NA
45			
46			
47			
48	Main results	<a href="#">#16c</a>	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
49			
50			
51			
52	7		
53			
54			
55	Other analyses	<a href="#">#17</a>	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses NA
56			
57			

## Discussion

1	Key results	<a href="#">#18</a>	Summarise key results with reference to study objectives	9
2				
3	Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into account sources of	11
4			potential bias or imprecision. Discuss both direction and magnitude of	
5			any potential bias.	
6				
7				
8	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation considering objectives,	11
9			limitations, multiplicity of analyses, results from similar studies, and	
10			other relevant evidence.	
11				
12				
13				
14	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external validity) of the study results	10-11
15				
16	<b>Other</b>			
17	<b>Information</b>			
18				
19				
20	Funding	<a href="#">#22</a>	Give the source of funding and the role of the funders for the present	12
21			study and, if applicable, for the original study on which the present	
22			article is based	
23				
24				

25 The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY.

26 This checklist was completed on 05. October 2021 using <https://www.goodreports.org/>, a tool made by the

27 [EQUATOR Network](#) in collaboration with [Penelope.ai](#)